Intraperitoneal FATE FT516 and Interleukin-2 (IL-2) With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Phase: PHASE1
Conditions: Ovarian Cancer, Fallopian Tube Adenocarcinoma, Primary Peritoneal Cavity Cancer
Sponsor: Masonic Cancer Center, University of Minnesota

 
Masonic Cancer Center, University of Minnesota 
Cancer Experimental Therapeutics Initiative (CETI) 
 
Intraperitoneal FATE FT516 and Interleukin-2 (IL-2) with Intravenous 
Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary 
Peritoneal Cancer  
CPRC # 2020LS001 
MT2020-07 
MacroGenics # ECT-MGA271-02 
IND 19674 
 
University of Minnesota 
Principal Investigator/IND Sponsor: 
Melissa A Geller, MD 
 
Co-Investigators: 
Department of Obstetrics and Gynecology:  
Peter A. Argenta, MD 
Deanna G. Teoh, MD 
Sally A. Mullany, MD 
Boris Winterhoff, MD 
Colleen Rivard, MD 
Britt Erickson, MD 
Rahel Ghebre, MD, MPH 
Andrea O'Shea, MD 
 
 
Collaborators: 
Jeffrey S. Miller, MD* 
David H. McKenna, Jr., MD* 
*Will not consent patients to enroll on study 
 
 
Biostatistician: 
Todd E. DeFor, MS 
 
 
Version Date: 
January 11, 2022 
 
 
Confidential 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 2 of 79 
CPRC #2020LS001 
 
Revision History 
 
Revision 
# 
Version 
Date 
Detail of Changes 
Consent 
Change? 
 
Mar 16 2020 
Original version for FDA 
n/a 
 
Apr 27 2020 
In response to FDA Clinical review received by email on Apr 
22 2020 (IND serial 0004) 
Other interim updates: 
 Add MacroGenics assigned study number to title page 
 Remove in-line filter requirement for FT516 as filter is only 
required as a safety precaution for IV infusion 
 Refine grade 3 organ toxicity definition within DLT 
definition 
 Section 5.1.8 clarify washout period of a least 14 days 
only applies to SOC tumor directed therapy to make 
consistent with Section 5.2.5 
 Add UMN study number for LTFU study  
 Section 7.4 – add paragraph regarding decision to treat on 
day of planned FT516  
 Section 8.5 – clarify pre-meds for FT516 also serve as 
pre-meds for IL-2 
 Section 9.1 and Section 9.2 – add a new column for Prior 
to 1st dose of study drug (baseline)  
 Section 9.2 - add PAR anti-HLA antibodies at baseline and 
Day 36 
yes 
 
Apr 29 2020 
In In response to FDA Clinical review received by email on 
Apr 28 2020 (IND serial 0005) – FDA approved version 
Other interim updates: 
Section 10.5: Advarra is the IRB of record, not UMN IRB 
Section 8.3 – edit DMSO reaction management section as 
not expected with low cell volume via IP infusion. 
 
yes 
 
Jun 22 2020 
Original to CPRC after MacroGenics review  
Other minor clarification and edits 
no 
 
Jul 15 2020 
In response to minor CPRC stip – Original to IRB 
Section 13.4 Update stopping rule language. 
Section 10.5 – clarify MacroGenics is only cc’ed on FDA 
submission for patients receiving enoblituzumab (Cohort 4 
and 5) 
no 
1 
Oct 27 2020 
 Clarify after CCPM throughout protocol including synopsis, 
schema, Section 4, Section 7.5 – study design that a 
minimum of 28 days between patient cohorts (end of DLT) 
and 14 days between the 1st and 2nd patients within a 
cohort and rules of enrollment including situations where 
Stage 1 Step 2 or Stage 2 are not activated. Re write for 
clarity 
 Synopsis –move rationale section down in synopsis to keep 
Study Design on one page 
 Synopsis and Section 5.1.6 - Update inclusion criteria for 
the placement of the IP catheter to read before the 1st dose 
of study directed drug as enoblituzumab is given before LD 
chemo. 
yes 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 3 of 79 
CPRC #2020LS001 
 
Revision 
# 
Version 
Date 
Detail of Changes 
Consent 
Change? 
 Synopsis and Section 5.2.1 add exclusion of women who 
are pregnant or plan on becoming pregnant in the next 6 
months 
 Section 7.2 – clarify additional doses of eno starts on Day 
22, not Day 21 
 Section 7.4 – add rules for window from CY/FLU 
administration of FT516, scheduling issues and skipped 
doses, match vital signs to wording in footnote in Section 
9.1 SOC care table 
 Section 7.8 and 7.9 – minor edits 
 Section 7.10 – add a statement that enoblituzumab may 
continue for Cohorts 4 and 5 
 Section 8.1 – clarify in header that IRR is for Cohorts 4 
and 5 only  
 Section 8.5 – update diphenhydramine dose information to 
match SOC 
 Section 8.6 – update CRS section regarding collection of 
IL-6 levels if CRS is suspected or diagnosed. Update 
Table 2, grade 2 hypotension management with new toci 
guidelines, add toci PI as ref., update Section 9.1 to reflect 
clarification 
  Section 9.1 – update based on updated Section 8.6 
 Section 9.2 – update research sample collection including 
added baseline safety samples for Fate, clarify the 9 
month safety samples are not required for Fate, reduce 
follow-up blood volumes for green top tubes to 30 ml per 
time point, delete PB and IP chimerisms, added new 
footnote for part of a green top tube to go to Fate to 
replace chimerisms run locally, other minor clarifications 
 Section 10.2 – add standard template language  
 Update Section 12.5 – record retention to new template 
langue 
 Other minor updates and clarifications 
2 
Jan 11 2022 
 Section 7.1 – add the of risk for spread of cancer cells that 
are located within the peritoneum to surrounding tissues 
with placement and use of IP catheter 
 Section 10.5 - update Advarra and Fate expedited 
reporting timeframes 
 Section 6.3, Section 7.8 - Clarify retreatment criteria of 
stable disease or better is based on iRECIST (iCR, iPR or 
iSD) not RECIST (CR, PR, SD) and if a iUPD at  the Day 
36 disease assessment, options regarding retreatment 
 Updated table of Key Abbreviations 
yes  
 
PI/IND Sponsor Contact Information: 
Melissa Geller, MD 
Department of Obstetrics and Gynecology 
420 Delaware Street SE MMC 395 
Minneapolis, MN 55455 
Phone: 612 626-3111  
Email: gelle005@umn.edu 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 4 of 79 
CPRC #2020LS001 
 
Key Abbreviations 
Abbreviation 
Definition 
ABW 
actual body weight 
ADCC 
antibody dependent cell-mediated cytotoxicity 
ADL 
activities of daily living 
AE 
adverse event 
ASTCT 
American Society for Transplantation and Cellular Therapy 
CAR 
chimeric antigen receptor 
CFR 
Code of Federal Regulations 
CNS 
central nervous system 
CRM 
continual reassessment method 
CRS 
cytokine release syndrome 
CTCAE 
Common Terminology Criteria for Adverse Events 
CY/FLU 
cyclophosphamide/fludarabine 
DLCO 
diffusing capacity of the lungs for carbon monoxide 
DLT 
dose limiting toxicity 
eCRF 
electronic case report form 
EOT 
end of treatment 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
GvHD 
graft-versus-host disease 
IB 
Investigator’s Brochure 
ICANS 
Immune effector Cell-Associated Neurotoxicity Syndrome 
ICE 
Immune Effector Cell-Associated Encephalopathy 
ICH 
International Conference on Harmonisation 
iCPD 
confirmed progressive disease based on iRECIST 
iCR 
complete response based on iRECIST 
IL-2 
Interleukin-2 
IND 
Investigational New Drug 
IP 
Intraperitoneal 
iPR 
partial response based on iRECIST 
IRB 
Institutional Review Board 
iRECIST 
Immune Response Evaluation Criteria in Solid Tumors 
IRR 
Infusion related reaction 
iSD 
stable disease based on iRECIST 
iUPD 
unconfirmed progressive disease based on iRECIST 
IV 
intravenous 
LTFU 
long-term follow-up 
MTD 
maximum tolerated dose 
NCI 
National Cancer Institute 
NK 
natural killer 
OS 
overall survival 
PBMC 
peripheral blood mononuclear cell 
PFS 
progression free survival 
PFT 
pulmonary function test 
SAE 
serious adverse event 
SOC 
Standard of care 
SUSAR 
Suspected Unexpected Serious Adverse Reaction 
TRM  
treatment related mortality 
ULN 
upper limit of normal 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 5 of 79 
CPRC #2020LS001 
 
Table of Contents 
Key Abbreviations ...................................................................................................................... 4 
Protocol Synopsis ...................................................................................................................... 8 
Schema.....................................................................................................................................11 
1 
Objectives ..........................................................................................................................12 
1.1 
Primary Objective.................................................................................................. 12 
1.2 
Secondary Objectives ........................................................................................... 12 
1.3 
Correlative Objectives ........................................................................................... 12 
2 
Background and Significance .............................................................................................12 
2.1 
Background........................................................................................................... 12 
2.2 
Natural Killer (NK) Cells ........................................................................................ 13 
2.2.1 
Natural Killer Cells as Immunotherapy .................................................................13 
2.2.2 
Clinical Outcomes of Allogeneic NK Cell Therapy ................................................14 
2.3 
FT516 ................................................................................................................... 15 
2.3.1 
Development of FT516 ........................................................................................15 
2.3.2 
Summary of Clinical Data.....................................................................................16 
2.3.3 
Summary of Nonclinical Data ...............................................................................17 
2.4 
Interleukin-2 .......................................................................................................... 17 
2.5 
Lymphodepletion with Cyclophosphamide and Fludarabine .................................. 18 
2.6 
Enoblituzumab ...................................................................................................... 18 
3 
Study Rationale..................................................................................................................18 
3.1 
Once Ovarian Cancer Recurs It Cannot be Cured ................................................ 18 
3.2 
Rationale for Using Enoblituzumab ....................................................................... 19 
3.3 
Rationale for Using FT516 IP Dosing .................................................................... 19 
4 
Study Design .....................................................................................................................21 
5 
Patient Selection ................................................................................................................23 
5.1 
Inclusion Criteria ................................................................................................... 23 
5.2 
Exclusion Criteria .................................................................................................. 25 
6 
Patient Screening and Study Enrollment ............................................................................26 
6.1 
Registration with the Masonic Cancer Center Clinical Trials Office ....................... 26 
6.2 
Patient Enrollment and Cohort Assignment ........................................................... 26 
6.3 
Patient Re-Treatment with FT516 ......................................................................... 26 
6.4 
Patients Who Do Not Begin Study Treatment ....................................................... 27 
7 
Treatment Plan ..................................................................................................................27 
7.1 
Peritoneal Catheter Placement (Day – 6 or earlier) ............................................... 27 
7.2 
Enoblituzumab (Day -6 then Day 22 and every 21 Days thereafter) - Cohort 4 and 5 
only 
28 
7.2.1 
Pre-Medications and Prophylaxis Guidelines .......................................................29 
7.2.2 
Management of Observed Infusion Related Reactions ........................................29 
7.3 
Preparative Regimen (Day -5 and Day -4) ............................................................ 32 
7.4 
FT516 and IL-2 (Day 1, Day 8, and Day 15).......................................................... 32 
7.5 
Monitoring for Dose Limiting Toxicities .................................................................. 34 
7.6 
Supportive Care .................................................................................................... 35 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 6 of 79 
CPRC #2020LS001 
 
7.7 
General Concomitant Medication Guidelines ........................................................ 35 
7.8 
Duration of FT516 / IL-2 Treatment and Possible Retreatment ............................. 35 
7.9 
Duration of Enoblituzumab (COHORT 4 or 5 ONLY) ............................................. 36 
7.10 
Duration of Study Participation .............................................................................. 36 
8 
Management of Selected Expected Toxicities Associated with Enoblituzumab and/or 
FT516/IL-2 Administration .........................................................................................................36 
8.1 
Known Infusion Related Reaction (IRR) to Enoblituzumab (Cohort 4 and 5) ......... 36 
8.2 
Infusion Related Reaction Secondary to the Infusion of FT516 ............................. 37 
8.3 
DMSO-Related Risks ............................................................................................ 38 
8.4 
Infection ................................................................................................................ 38 
8.5 
IL-2 ....................................................................................................................... 39 
8.6 
Cytokine Release Syndrome (CRS) or CRS-Like Symptoms ................................ 39 
8.7 
Tumor Lysis Syndrome ......................................................................................... 41 
8.8 
Neurotoxicity ......................................................................................................... 42 
8.9 
Vascular Leak Syndrome ...................................................................................... 43 
8.10 
Enoblituzumab Adverse Events ............................................................................ 44 
9 
Clinical Evaluations and Procedures ..................................................................................44 
9.1 
Required Clinical Care Evaluations ....................................................................... 46 
9.2 
Patient Research Related Evaluations .................................................................. 48 
9.2.1 
Intraperitoneal (IP) Fluid Collection ......................................................................49 
9.2.2 
Tumor Biopsies ....................................................................................................50 
10 
Event Monitoring, Documentation, and Reporting ...........................................................50 
10.1 
Event Terminology ................................................................................................ 51 
10.2 
Event Monitoring and Documentation Requirements ............................................ 53 
10.3 
Dose Limiting Toxicity Event/Stopping Rule Documentation and Reporting .......... 54 
10.3.1 
During Fast-Track Enrollment Only ......................................................................54 
10.3.2 
Dose Limiting Toxicity (All Patients) .....................................................................55 
10.3.3 
Early Stopping Rule Events .................................................................................55 
10.4 
SAE and Death Documentation ............................................................................ 56 
10.5 
Expedited Reporting Requirements ...................................................................... 56 
11 
Investigational Products Information ...............................................................................57 
11.1 
Enoblituzumab ...................................................................................................... 57 
11.1.1 
Availability ............................................................................................................57 
11.1.2 
Storage ................................................................................................................57 
11.1.3 
Preparation ..........................................................................................................57 
11.1.4 
Potential Toxicities ...............................................................................................57 
11.2 
FT516 ................................................................................................................... 58 
11.3 
Interleukin-2 .......................................................................................................... 58 
12 
Study Data Collection and Monitoring .............................................................................58 
12.1 
Data Management ................................................................................................ 58 
12.2 
Case Report Forms ............................................................................................... 59 
12.3 
Data and Safety Monitoring Plan (DSMP) ............................................................. 59 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 7 of 79 
CPRC #2020LS001 
 
12.4 
Study Monitoring ................................................................................................... 59 
12.5 
Record Retention .................................................................................................. 60 
13 
Statistical Considerations ...............................................................................................60 
13.1 
Study Design, Objectives and Endpoints .............................................................. 60 
13.2 
Sample Size.......................................................................................................... 62 
13.3 
Statistical Analysis ................................................................................................ 62 
13.4 
Monitoring Guidelines (Early Study Stopping Rules) ............................................. 63 
14 
Ethical and Regulatory Considerations ...........................................................................63 
14.1 
Good Clinical Practice ........................................................................................... 63 
14.2 
Ethical Considerations .......................................................................................... 63 
14.3 
Informed Consent ................................................................................................. 64 
15 
References .....................................................................................................................64 
Appendix I – GOG PS Scale and NYHA Classification ..............................................................68 
Appendix II - iRECIST version 1.1 .............................................................................................69 
Appendix III – Expected Toxicities - Preparative Regimen and IL-2 ..........................................76 
Appendix IV – Management of Clinical Neurotoxicity ................................................................77 
 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 8 of 79 
CPRC #2020LS001 
 
Protocol Synopsis 
Intraperitoneal FATE FT516 and Interleukin-2 (IL-2) with Intravenous Enoblituzumab in Recurrent 
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer  
 
Study Design: 
This is a single center Phase I clinical trial of FT516 administered intraperitoneally (IP) once a week 
for 3 consecutive weeks for the treatment of recurrent gynecologic cancers. As this is an early 1st in 
human study and the 1st intraperitoneal infusion of FT516, the safety of FT516 is confirmed prior to 
adding enoblituzumab as an intravenous infusion approximately 1 week prior to the 1st dose of FT516 
and every 3 weeks beginning on Day 22 (1 week after the last dose of FT516). Each dose of FT516 is 
followed directly by an IP infusion of interleukin-2 (IL-2) to facilitate natural killer (NK) cell survival. A 
short course of outpatient lymphodepletion chemotherapy is given prior to the 1st dose of FT516. 
 
FT516 is an off the shelf product comprised of allogeneic natural killer (NK) cells, expressing high-
affinity non-cleavable CD16 (FT516). Enoblituzumab is an Fc-optimized monoclonal antibody that 
targets B7-H3 which is highly expressed on ovarian cancer. 
 
This study is conducted in two consecutive stages using the following treatment plan:  
Cohort 
Treatment Plan 
1 (start) 
IP FT516 monotherapy 9 x 10^7 cells/dose on Day 1, 8, and 15 
2 
IP FT516 monotherapy 3 x 10^8 cells/dose on Day 1, 8, and 15 
3 
IP FT516 monotherapy 9 x 10^8 cells/dose on Day 1, 8, and 15 
4 
Safe dose (MTD-1) from 1st 3 levels + IV enoblituzumab on Day -6  
5 
Highest dose (MTD) from 1st 3 levels + IV enoblituzumab on Day -6 
A minimum of 28 days must separate each cohort. Within a 3 patient cohort, a minimum of 14 days 
must separate the 1st and 2nd patient within a cohort. All patients are assessed for Dose Limiting Toxicity 
(DLT) as defined in the Schema and in Section 7.5 
 
Stage 1 Step 1 uses a fast-track design (1 patient per Cohort) with a minimum of 28 days between 
each patient until one of the following:  
 The 1st occurrence of a pre-defined adverse event within 28 days of the cell infusion (defined as 
Grade 3 abdominal pain for > 48 hours despite standard analgesics or Grade 3 infusion related 
reaction) at which point the study moves to Step 2 and the cohort size increases from 1 to 3 patients 
with 2 additional patients added to the current cohort. Escalation in Step 2 continues until the 1st DLT 
event at which point Stage 2 (CRM) is activated. If Cohort 5 is completed with 10 patients enrolled at 
the MTD without a DLT, Stage 2 (CRM) is not used. 
 The 1st occurrence of a DLT the study moves directly to Stage 2 (CRM) as detailed below and Step 
2 is not used. 
 Cohort 5 is completed without a pre-defined AE or a DLT – neither Step 2 nor Stage 2 is used if a 
total of 10 patients are enrolled in Cohort 5 to complete the study. 
 
Stage 2 is initiated at the 1st DLT (as defined in Schema and in Section 7.5). The study design 
changes to the continual reassessment method (CRM). Enrollment occurs in cohorts of three with a 
minimum of 14 days between the 1st and 2nd patient. Each new cohort of three patients are sequentially 
assigned to the most appropriate dose by the study statistician based on the updated toxicity 
probabilities once the 3rd patient in a cohort reaches Day 28 (end of DLT period). The MTD will be 
identified by the minimum of the following criteria: (1) the total Stage 2 sample size of 25 is exhausted, 
(2) 10 consecutive patients are enrolled at the same dose plan or (3) the probability that the next 5 
patients will be allocated to the same dose plan, based on the current estimate of the probability of 
toxicity, exceeds 90%. 
 
For study endpoints, follow-up continues until disease progression and then for survival only for 1 year 
from the 1st dose of FT516.  
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 9 of 79 
CPRC #2020LS001 
 
Investigational 
Products:  
 Enoblituzumab provided by MacroGenics, Inc. 
 FT516 provided by Fate Therapeutics 
 IL-2 paid for by the study (research grants) 
Rationale for 
the 
Combination: 
Based on data showing that within the ovarian cancer tumor microenvironment surface expression of 
CD16a on NK cells is diminished, we hypothesize that the FT516 cellular product containing a non-
cleavable CD16 will bypass the low CD16 expression issue and maximize NK cell cytotoxicity. 
Enoblituzumab is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276). 
B7-H3 is an inhibitory immune checkpoint molecule that is widely expressed by a number of different 
tumor types and may play a key role in regulating the immune response. It is therefore hypothesized 
that the combination of FT516 with enoblituzumab will maximize NK cell cytotoxicity in patients with 
ovarian cancer. 
Long-Term 
Follow-Up: 
After 1 year, follow-up transfers to a separate long-term follow-up (LTFU) study (CPRC #2020LS072) 
to continue the FDA’s required 15-year follow-up after treatment with a genetically modified cell 
therapy. Participation in the LTFU study is mandatory. 
Primary 
Objective: 
To determine the maximum tolerated dose (MTD) of FT516 monotherapy when administered via 
intraperitoneal catheter with IP IL-2 and in combination with intravenous (IV) enoblituzumab in patients 
with recurrent ovarian, fallopian tube, and primary peritoneal cancer.  
Secondary 
Objectives: 
 To characterize the toxicities associated with IP FT516 and IL-2 when administered as monotherapy 
and after IV enoblituzumab  
 To estimate progression-free survival (PFS) and overall survival (OS) at 6 months and 12 months 
from the 1st dose of FT516 
 To gain preliminary efficacy information with this treatment combination 
Correlative 
Objectives: 
Blood and intraperitoneal washings:  
 To characterize the pharmacokinetics (PK) of FT516 monotherapy and in combination with 
enoblituzumab in the peritoneal fluid, peripheral blood and tumor biopsy samples.  
 To assess the association of PK and pharmacodynamics (PD) in the peritoneal fluid of FT516 
monotherapy and in combination with enoblituzumab in the peritoneal fluid in recurrent ovarian, 
fallopian tube, and primary peritoneal cancer with safety and anti-tumor activity 
 To measure function of in vivo expanded adoptively transferred FT516 
Tumor biopsies: 
 To assess tumor microenvironment 
Inclusion 
Criteria: 
 Recurrent epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer meeting one of the 
following minimal prior treatment requirement (no maximum number of prior treatments): 
platinum resistant: FT516 may be given as 2nd line (first salvage therapy) 
platinum sensitive: FT516 may be give as 3rd line therapy (second salvage therapy) 
 Must have measurable disease per iRECIST1.1 within the abdomen and pelvis assessed within 42 
days of the 1st FT516 infusion   
 Extra-peritoneal disease is permitted; however each lesion must be <5 cm in diameter   
 Agrees to the placement of an intraperitoneal catheter before the 1st dose of study directed drug 
(chemotherapy or enoblituzumab - Cohort 4 and 5) and remains in place through Day 36 or longer 
 ≥ 18 years of age at time of consent signing 
 GOG performance status ≤ 2 
 Adequate organ function 
 Provides written consent to the companion LTFU study CPRC#2020LS072  
 Voluntary written consent for this study 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 10 of 79 
CPRC #2020LS001 
 
Exclusion 
Criteria: 
 Pregnant or planning on becoming pregnant in the next 6 months 
 Known allergy to the following FT516 components: albumin (human) or DMSO 
 Any known condition that requires systemic immunosuppressive therapy (> 5mg prednisone daily 
or equivalent) during the FT516 dosing period (3 days before the 1st dose through 14 days after 
the last dose) excluding pre-medications – inhaled and topical steroids are permitted 
 Receipt of any investigational agent within 28 days prior to the first dose of investigational product  
 Known seropositive for HIV or known active Hepatitis B or C infection with detectable viral load by 
PCR 
Accrual: 
Between 14 and 31 patients based on toxicity (includes 10 patients treated at the MTD) 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 11 of 79 
CPRC #2020LS001 
 
Schema 
 
 
 
 
 
 
 
 
             disease reassessement  per SOC 
 
      
 
 
                     and survival 
  
 
 
     FT516 IP/IL-2 IP Dosing 
 
End of 
 
 
          CY/FLU     #1 
        #2 
 #3 
 
          DLT        repeat CT   
 
screening and 
IP catheter placement  
      
 
 
 
 
 
 
 
 
 
Move to 
LTFU study 
 
 
 
 
 
 
 
 
 
 
 
Study Day 
       -6   -5   -4         1             8 
      15             22  
 29             36   
   43 and       6 months    12 months 
IP washing    x# 
 
               x 
        x               x 
         x  
    x 
        x#  
   every 3 wks 
 
# biopsy if feasible, at time of catheter placement and removal  
                           remove IP catheter unless re-treatment 
      
      Enoblituzumab 15 mg/kg IV 1 day before lymphodepleting chemotherapy (LEVEL 4 and LEVEL 5 only) 
 
CY/FLU Lymphodepleting Chemo: Fludarabine 25 mg/m2 IV followed by CY 300 mg/m2 IV) given on 2 consecutive days with a minimum of 48 
hours between the last dose of Flu and 1st dose of FT516 (e.g. day -5, day-4) 
 
FT516 IP at assigned dose* followed directly by IL-2 IP 6 MIU on Days 1, 8, and 15  
 
Enoblituzumab 15 mg/kg IV continues once every 3 weeks beginning on Day 22 and continuing every 3 weeks until disease progression or 
unacceptable toxicity. (LEVEL 4 and LEVEL 5 only) 
 
Day 29: End of DLT assessment period  
Day 36: Disease reassessment with CT of chest/abd/pelvis – remove catheter if no retreatment or if retreatment is planned administer in an identical 
schedule to with CY/FLU to start 1-2 days after next planned enoblituzumab (on Day 43). 
 
Follow-up: for disease response until disease progression and then survival only per standard of care for 1 year from the 1st dose of FT516  
 
*FT516 Dose Level Assignment  
Cohort 
FT516 Dose IP (cells per dose) 
Enrollment Plan - A minimum of 28 days must separate each cohort. Within a 3 patient 
cohort, a minimum of 14 days must separate the 1st and 2nd patient within a cohort. All 
patients are assessed for Dose Limiting Toxicity (DLT) as defined below and in Section 7.5 
1 
Monotherapy: IP FT516 at 9 x 10^7 
cells/dose on Day 1, 8, and 15 
 Stage 1, Step 1: Begin at Level 1. Enroll one patient per level until one of the following occurs 
within 28 days of 1st FT516 dose: Abdominal pain that is unresponsive to standard analgesics 
lasting more than 48 hours not attributable to disease status OR Grade 3 infusion related 
reaction (per CTCAE V5) OR 1st DLT as defined below. Note: if a DLT occurs during Fast-
track (Step 1), enrollment moves directly to Stage 2 CRM and Step 2 is not used. If Cohort 5 
is completed (N=10) without a pre-defined AE or a DLT – neither Step 2 nor Stage 2 is used. 
 Stage 1, Step 2: Increase patient cohorts to 3 and continue sequential dose escalation in 
cohort of 3 patients while assessing for DLT as defined below. At the 1st DLT switch to 
Stage 2. If Cohort 5 is completed (N=10) without a DLT, Stage 2 (CRM) is not used. 
 At the 1st DLT, Stage 2 is initiated and enrollment continues using the continual 
reassessment method (CRM), enrolling cohorts of 3 patients at the most appropriate level as 
determined by the study statistician once the 3rd patient in a cohort reaches Day 28 (end of 
DLT period) until 25 patients are enrolled by CRM or 10 consecutive patients are enrolled at 
the same level or the probability that the next 5 patients will be allocated to the same level 
based on the current estimate of the probability of toxicity, exceeds 90%. 
2 
Monotherapy: IP FT516 at 3 x 10^8 
cells/dose on Day 1, 8, and 15 
3 
Monotherapy: IP FT516 at 9 x 10^8 
cells/dose on Day 1, 8, and 15 
4 
Safe FT516 dose (MTD-1) from 1st 3 
levels + IV enoblituzumab on Day -6  
5 
Highest FT516 dose (MTD) from 1st 3 
levels + IV enoblituzumab on Day -6 
 
Dose Limiting Toxicity (DLT) is defined as any treatment emergent toxicity at least possibly related to the study treatment meeting one of the following 
criteria based on CTCAE v5 within 28 days (within 14 days for ascites) of the 1st FT516 infusion (for Cohort 4 and 5, DLT assessment starts with 
enoblituzumab and continues for 28 days after 1st FT516): 
• 
Grade 3 organ toxicity (pulmonary, hepatic, renal, or neurologic) not pre-existing and lasting more than 72 hours  
• 
Any non-hematologic Grade 4 or 5 toxicity 
• 
Neutrophil count decreased ≥ Grade 4 that persists at Day 28 despite use of growth factor support 
• 
Grade 3 abdominal pain lasting more than 4 consecutive days and not controlled by standard analgesics 
• 
Grade 3 or greater ascites within 14 days after FT516 administration in patients who had no ascites or Grade 1 ascites at enrollment and is not 
attributable to disease progression 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 12 of 79 
CPRC #2020LS001 
 
1 Objectives 
1.1 Primary Objective 
The primary objective of the study is to determine the maximum tolerated dose 
(MTD) of FT516 monotherapy when administered via intraperitoneal catheter with 
IP IL-2 and in combination with intravenous enoblituzumab in patients with 
recurrent ovarian, fallopian tube, and primary peritoneal cancer.  
1.2 Secondary Objectives 
 To characterize the toxicities associated with IP FT516 and IL-2 when 
administered as monotherapy and after IV enoblituzumab.  
 To estimate progression-free survival (PFS) and overall survival (OS) at 6 
months and 12 months from the 1st dose of FT516. 
 To gain preliminary efficacy information with this treatment combination. 
1.3 Correlative Objectives 
Blood and intraperitoneal washings are collected prior to treatment and at several 
time points through Day 42 (blood) or Day 36 (peritoneal fluid) for study related 
analysis: 
 To characterize the pharmacokinetics (PK) of FT516 monotherapy and in 
combination with enoblituzumab in the peritoneal fluid, peripheral blood and 
tumor biopsy samples.  
 To assess the association of PK and pharmacodynamics (PD) in the peritoneal 
fluid of FT516 monotherapy and in combination with enoblituzumab in recurrent 
ovarian, fallopian tube, and primary peritoneal cancer with safety and anti-tumor 
activity. 
 To measure function of in vivo expanded adoptively transferred FT516. 
 
Tumor biopsies (if feasible) at the time of catheter placement and catheter 
removal for study related analysis including: 
 To assess tumor microenvironment.  
 
2 Background and Significance  
2.1 Background 
Dr. Jeffrey Miller and collaborators from the University of Minnesota pioneered the 
development of allogeneic haplo-identical natural killer (NK) cell cancer 
immunotherapy beginning in the year 2000. While previous clinical trials of 
methods to induce autologous NK cell activity demonstrated safety, such as 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 13 of 79 
CPRC #2020LS001 
 
prolonged treatment with low-dose subcutaneous IL-2, higher doses of IV IL-2 and 
infusions of ex vivo IL-2 activated NK cells, these methods failed to demonstrate 
clinical efficacy. As the concept of “missing self” and the rules of NK cell 
alloreactivity emerged, interest in the use of haplo-identical NK cells to increase 
anti-tumor activity was established. It was believed that effector NK cells educated 
in haplo-identical healthy donors could induce stronger graft-versus-leukemia 
effects since these cells were not exposed to immunosuppressive mechanisms 
found in cancer patients. Additionally, it was further hypothesized that haplo-
identical donors would provide a higher frequency of alloreactive NK cells (i.e., NK 
cells with attenuated inhibitory receptor signaling due to the major 
histocompatibility complex class I mismatch between the haplo-identical NK cells 
and the patient’s tumor cells). 
 
We established the safety and success of adoptive transfer of allogeneic NK cell 
products in a trial using haplotype mismatched, related-donor NK cell products  
(mean NK cell dose of 2 (range 1-6.2) x107 cells/kg from a single donor apheresis), 
followed by subcutaneous IL-2 to induce in vivo NK survival and expansion (Miller 
2005). Importantly, successful expansion of the allogeneic NK cells was achieved 
after a lympho-depleting regimen of high dose cyclophosphamide (Cy) and 
fludarabine (Flu). This chemotherapy regimen, delivered prior to NK cell transfer, 
transiently prevents patient T cells from rejecting adoptively transferred NK cells 
creating an environment conducive to NK cell expansion. Complete remissions in 
AML correlated with in vivo NK expansion and higher proportions of circulating 
(and functional) NK cells. This treatment approach leads to potent anti-tumor 
killing. To date, we have treated over 150 patients with refractory AML and other 
cancers, including ovarian, with adoptively transferred NK cells (INDs 8847, 
13659,14448) utilizing our standard platform of Cy/Flu, followed by delivery of 
exogenous IL-2 or IL-15 to promote in vivo NK cell activation and expansion. 
Although these results are an improvement over standard salvage therapy for 
patients with refractory leukemia (expected CR rate of 30% with NK therapy vs 
10% with current SOC), they suggest that adoptive cell therapy in its current form 
requires additional anti-tumor activity. (Bachanova 2014) 
2.2 Natural Killer (NK) Cells 
2.2.1 Natural Killer Cells as Immunotherapy 
Cancer immunotherapy is a rapidly evolving field that has transformed the 
treatment of many tumor types including solid tumors. However, despite important 
advances, the majority of patients will either not respond or eventually experience 
disease relapse. Particularly in solid tumors, the mechanisms of tumor resistance 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 14 of 79 
CPRC #2020LS001 
 
to cancer immunotherapies are diverse and include the ability of tumors to form 
physical and immunologic barriers to immune effector cells such as T cells and 
NK cells (Melero 2014). Further understanding of the biology that enables these 
cells to enter tumors and retain anti-tumor cytotoxic activity is important in order to 
maximize their clinical benefit for patients. 
NK cells are so named for their “natural” ability to kill cancer cells without prior 
sensitization (Kiessling 1975). NK cells kill cancer cells by multiple mechanisms 
including direct cytotoxicity, cytokine secretion, and antibody dependent cell-
mediated cytotoxicity (ADCC): 
 Direct cytotoxicity through the targeted release of perforins and granzymes. 
Importantly, while MHC-I deficient cells evade CD8 T-cell recognition, they are 
preferential targets for NK cells and are highly susceptible to NK cell-mediated 
killing (Malmberg 2017). 
 Cytokines, including interferon-gamma (IFN) and tumor necrosis factor-alpha 
(TNF) promote direct tumor cell killing (Wang R 2012). 
 ADCC, which occurs when an antibody binds to a tumor cell and the antibody’s 
Fc region binds to the CD16 receptor on NK cells, triggering a cytotoxic 
response towards the tumor cell (Waldhauer 2008; Wang, W 2015). 
In addition to direct effects on tumor cells, NK cells can interact with the adaptive 
immune system to generate and maintain adaptive immune responses against 
cancer cells: 
 Killing of tumor cells by NK cells results in the release of tumor antigens for 
recognition by the adaptive immune system (Dahlberg 2015). 
 NK cells upon activation secrete cytokines that recruit and activate endogenous 
T cells. Importantly, activated NK cells are potent producers of chemokines 
such as CXCL10, CCL4, and CCL5, which are known recruitment factors for T 
cells. Cytokines secreted by NK cells also induce maturation of dendritic cells, 
which serve as antigen-presenting cells to mediate adaptive immune 
responses (Smyth 2002). 
2.2.2 Clinical Outcomes of Allogeneic NK Cell Therapy 
In clinical investigations, allogeneic NK-cell therapies have been well-tolerated 
with documented anti-tumor activity. More than 500 patients across 30 completed 
clinical studies have received allogeneic NK cells (Veluchamy 2017). Notably, and 
unlike allogeneic T cell therapies, allogeneic NK cells have not been associated 
with graft-vs-host disease (GvHD). Furthermore, with a single exception (Cooley 
2019), allogeneic NK cell therapies have not been associated with cytokine release 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 15 of 79 
CPRC #2020LS001 
 
syndrome (CRS) or neurotoxicity, common complications observed with CAR-T 
cell therapies. Complete remission rates ranging from 21% to 53% have been 
observed following a single administration of allogeneic NK cells in subjects with 
relapsed/refractory acute myelogenous leukemia (AML) (Miller 2005; Bachanova 
2014; Romee 2016), and in subjects with poor prognosis refractory non Hodgkin 
lymphoma (Bachanova 2018). Clinical responses have also been reported in 
subjects with solid tumors including non-small cell lung cancer (Iliopoulou 2010; 
Tonn 2013), as well as in subjects with platinum-resistant ovarian cancer 
(Geller 2011), melanoma (Arai 2008), and renal cell carcinoma (Arai 2008). 
2.3 FT516 
2.3.1 
Development of FT516 
FT516 is an allogeneic natural killer (NK) cell immunotherapy derived from a clonal 
human-induced pluripotent stem cell (iPSC) line, engineered to express a high-
affinity, non-cleavable CD16 (hnCD16) Fc receptor. The clonal master cell bank 
(MCB) used for the production of FT516 was generated by selecting and 
expanding a single, well-characterized iPSC clone with a single, defined hnCD16 
transgene integration site. The use of a clonal MCB as the starting material for 
routine Current Good Manufacturing Practices production of FT516 is intended to 
directly address many of the limitations associated with patient- and donor-specific 
cell therapies. Notably, many doses of FT516 drug product can be uniformly 
produced in a single manufacturing campaign. These doses of drug product are 
homogeneous and can be (i) tested to assure compliance with a pre-defined 
quality specification, (ii) cryopreserved in an infusion medium, and (iii) stored to 
maintain a sustainable inventory. As such, in the clinical setting, FT516 has 
off-the-shelf availability for use in multi-dose regimens, which may prove critical for 
driving long-term durable responses in patients with progressing disease. 
The engineered features of FT516 are designed to result in increased activity 
against target tumor cells as monotherapy and when combined with monoclonal 
antibodies (mAbs) that can mediate antibody dependent cell cytotoxicity (ADCC). 
Important functional attributes of FT516 include the following: 
 FT516 is expected to have superior effector function compared to patients’ 
endogenous NK cells, which are diminished in number and poorly functional due 
to prior treatment regimens (e.g., chemotherapy) and tumor suppressive 
mechanisms. FT516 maintains the “natural cytotoxicity” that is potent and 
specific to transformed cells. 
 FT516 expresses an hnCD16 Fc receptor. The high-affinity CD16 variant arising 
from a naturally occurring 158V polymorphism has demonstrated enhanced 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 16 of 79 
CPRC #2020LS001 
 
ADCC when combined with therapeutic mAbs in nonclinical studies. In clinical 
studies, patients whose endogenous NK cells express the high affinity CD16 Fc 
receptor variant, higher objective response rates, and increased progression-
free survival (PFS) were observed with treatment with rituximab, cetuximab, and 
trastuzumab (Cartron 2002; Musolino 2008; Bibeau 2009). In addition, hnCD16 
contains the genetic alteration (S179P) that prevents cleavage of CD16 by the 
metalloproteinase ADAM17 (Lajoie 2014; Jing 2015) that is a mechanism in the 
regulation of NK cell activity (Romee  2013). 
 
The product candidate is being investigated in an open-label, multi-dose Phase 1 
clinical trial as a monotherapy for the treatment of acute myeloid leukemia and in 
combination with CD20-directed monoclonal antibodies for the treatment of 
advanced B-cell lymphoma (NCT04023071). Subjects are eligible to receive up to 
three once-weekly doses over a one-month treatment cycle, which treatment cycle 
may be repeated. FT516 cells are formulated in an infusion medium consisting of 
Plasma-Lyte A (pH 7.4) with albumin (human) (10% w/v) and dimethyl sulfoxide 
(7.5% v/v), and is administered intravenously. 
2.3.2 Summary of Clinical Data 
A Phase I study of FT516 in subjects with advanced hematologic malignancies is 
ongoing. Enrolled subjects may receive up to a total of six doses of FT516 by 
intravenous (IV) infusion, each cycle of three doses preceded by low dose 
chemotherapy and followed by supplemental IL-2. As of the Development Safety 
Update Report (DSUR) data cutoff date of 31 January 2020, three subjects have 
been treated with FT516 in the Phase I study, with two subjects treated with 
Regimen A (FT516 IV monotherapy) and one subject treated with Regimen B 
(FT516 IV plus rituximab) as follows: 
Regimen 
NK Cells per 
Dose 
Number of 
Subjects 
Total Number of 
FT516 Doses 1 
Regimen A: FT516 
9 x 107 cells 
2 
9 
Regimen B: FT516 + rituximab 
3 x 107 cells 
1 
6 
1 Total number of FT516 IV doses represents the cumulative number of doses administered to all 
subjects enrolled at the prescribed FT516 dose. As of the DSUR data cutoff date, enrolled subjects 
each received between 3 and 6 doses of FT516: Regimen A (9 × 107 cells) – 1 subject received 6 
doses and 1 subject received 3 doses; Regimen B (3 × 107 cells) – 1 subject received 6 doses. 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 17 of 79 
CPRC #2020LS001 
 
As of the DSUR data cutoff date, no serious clinical risks related to intravenous 
FT516 had been identified. No subjects had experienced cytokine release 
syndrome (CRS), neurotoxicity or graft vs. host disease. In Regimen A, no dose-
limiting toxicities (DLTs), or FT516-related serious adverse events (SAEs), were 
reported. In Regimen B, a protocol-defined dose-limiting toxicity (DLT) of Grade 4 
neutropenia in the absence of fever or signs and symptoms of infection was 
reported; however, multiple factors other than FT516, including baseline clinical 
factors, effects of lympho-conditioning and the known toxicity profile of rituximab, 
may have contributed to the neutropenia. 
2.3.3 Summary of Nonclinical Data 
Nonclinical in vitro and in vivo studies were conducted using cryopreserved FT516-
R, the non-GMP research use equivalent of FT516. No safety concerns were 
identified. Data from nonclinical studies were notable for the following: 
 No safety concerns have been observed. A three-month Good Laboratory 
Practice (GLP) toxicology study revealed no FT516-R related serologic or 
histologic evidence of toxicity with repeated dosing at doses calculated to be 
26-times higher than the proposed clinical starting dose based on allometric 
scaling. Furthermore, no evidence of tumorigenicity was identified. 
 The biodistribution of FT516-R cells is consistent with the expected tissue 
distribution following intravenous (IV) administration of adoptive cells, 
predominantly in highly perfused tissues such as lungs, spleen, heart, and liver. 
Persistence data demonstrates that FT516-R cells are cleared within 28 days 
post-administration, which was confirmed also at 42 days post-administration, 
and with no evidence of permanent engraftment. 
 Supporting the role of CD16 in enhancing ADCC, ligation of hnCD16 enhanced 
NK-cell activation as measured by calcium flux and phosphorylation of 
signaling cascades. Furthermore, the combination of FT516-R and antibodies, 
including rituximab, resulted in enhanced anti-tumor activity, as compared to 
antibody alone, FT516 alone, and peripheral blood NK cells alone. 
2.4 Interleukin-2  
IL-2 remains the only FDA approved drug that is capable of promoting NK cells 
activation and survival. There is also broad clinical experience and we have 
considerable clinical experience with the low doses of IL-2 proposed here. 
Although IL-2 may stimulate regulatory T cells (Treg), which can suppress NK 
cells, there are no other current options without exploring experimental agents 
(such as IL-15). Therefore, we believe that IL-2 is currently the best choice for this 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 18 of 79 
CPRC #2020LS001 
 
first in human study while we explore the merits of IL-2 vs IL-15 and other cytokines 
in pre-clinical studies. 
2.5 Lymphodepletion with Cyclophosphamide and Fludarabine  
The importance of lymphodepleting chemotherapy has been well demonstrated in 
mouse experiments and was first proposed by the National Cancer Institute (NCI) 
in the context of melanoma specific CTL by Rosenberg and colleagues. (Dudley 
2002) Lymphodepleting conditioning prior to adoptive transfer of lymphocytes is 
thought to promote persistence of adoptively transferred lymphocytes by creating 
"immunologic space” and providing a pool of homeostatic cytokines such as IL-15. 
The use of Cy/Flu-mediated lymphodepletion at the proposed doses and schedule 
is consistent with our previous human experience. (Miller 2005, Bachanova 2014) 
2.6 Enoblituzumab 
MGA271 (enoblituzumab, also known as RES242) is a humanized immunoglobulin 
(Ig) G1/kappa monoclonal antibody (mAb) that binds B7 homolog 3 (B7-H3), also 
referred to as CD276, a member of the B7 family of ligands that bind to receptors 
on lymphocytes and regulate immune responses. This agent is being developed 
by MacroGenics, Inc. B7-H3 is overexpressed on a number of tumor types and the 
primary mechanism of action for MGA271 is thought to be via antibody-dependent 
cellular cytotoxicity (ADCC). MGA271 comprises an engineered human IgG1 
fragment crystallizable (Fc) domain that imparts increased affinity for the human 
activating Fc-gamma receptor (FcγR) IIIA (CD16A) and decreased affinity for the 
human inhibitory FcγRIIB (CD32B). (Enoblituzumab IB) 
 
 
3 Study Rationale 
3.1  Once Ovarian Cancer Recurs It Cannot be Cured 
Ovarian cancer is the most lethal gynecologic malignancy. The estimated 5-year 
survival is 48% for all stages of ovarian cancer, and 29% for distant disease. 
Notably, 59% of women with ovarian cancer present with Stage III or IV disease, 
for which the rate of recurrence is 70 to 90% for Stage III and 90 to 95% for Stage 
IV. (SEERS) Women who recur cannot be cured with current therapies. Our long 
term objective is to exploit the innate immune system to treat ovarian cancer and 
substantially improve survival rates. 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 19 of 79 
CPRC #2020LS001 
 
3.2 Rationale for Using Enoblituzumab 
Clinical experience and trials have not identified an effective cancer antibody for 
ovarian cancer compared to others solid tumors responding to HER2 and EGFR 
targeted antibodies. Enoblituzumab is an Fc optimized humanized IgG1 
monoclonal antibody that binds to B7-H3 (CD276). B7-H3 is widely expressed by 
a number of different tumor types, including a majority of ovarian cancers and 
ovarian cancer stroma (MacGregor 2019), and may play a key role in regulating 
the immune response. It has been reported that B7-H3 is expressed on at least 
93% of ovarian tumors by immunohistochemical tissue microarray analysis on 
tumor specimens. (Zhang 2010) Interestingly, in the same study showed B7-H3 
was expressed on 78% endothelium of tumor-associated vasculature from Stage 
III and IV patients but less so in early stage patients. This suggests that targeting 
B7-H3 in advanced ovarian cancer may dual target the tumors themselves and the 
tumor microenvironment in the advanced patients fitting eligibility for this trial. 
3.3 Rationale for Using FT516 IP Dosing 
Based on our published in vivo mouse data (Hermanson 2016) our current platform 
for NK cell therapy in ovarian cancer delivers NK cells IP as we have seen 
significant inhibition of ovarian cancer growth using this delivery. As ovarian cancer 
is an intraperitoneal disease, rarely metastasizing beyond the abdominal cavity, 
therapy delivered directly to the tumor site makes intuitive sense. Recent studies 
conducted by our collaborators defined the lymphocyte population within the 
peritoneal fluid (PF) of women with high-grade serous ovarian cancer (Figure 1). 
They found that women with ovarian cancer had a significantly lower percentage 
of NK cells in the PF compared to women with benign disease. Importantly, the 
ovarian cancer patients with lower number of NK cells had significantly lower 
survival.  
 
Figure 1 
 
This data provides the rationale for delivering the FT516 product directly within the 
peritoneal cavity. In addition, we recently completed a clinical trial where we 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 20 of 79 
CPRC #2020LS001 
 
developed a 7-day culture process using a GSK3 inhibitor and IL-15 to 
manufacture 
modulated 
adaptive 
NK 
cells 
(FATE-NK100) 
from 
CMV+ haploidentical donors for adoptive transfer. The phase I Apollo trial tested 
the maximum tolerated dose/maximum feasible dose (MTD/MFD) of FATE-NK100 
administered intraperitoneally (IP) to treat platinum-sensitive or -resistant recurrent 
ovarian, fallopian tube, and primary peritoneal cancer. FATE-NK100 via IP port 
was tested using 3 dose cohorts ([DC]; 1 × 107 cells/kg; >1 × 107 cells/kg to ≤3 × 
107 cells/kg; or >3 × 107 to ≤10 × 107 cells/kg) after lympho-conditioning with 
fludarabine 25 mg/m2 IV and cyclophosphamide 300 mg/m2 IV on days −6 and −5. 
After FATE-NK100 infusion on day 0, rhIL-2 at 6 million IU was given IP 3 times a 
week for 6 doses for in vivo NK activation. Nine patients were treated with no dose-
limiting toxicities (DLTs). Retreatment based on clinical benefit was performed on 
3 patients (33%), 2 following stable disease (DC 2) and 1 with partial remission 
(48% tumor reduction, DC 3). We found that the allogeneic product cells persist 
and have enhanced function compared to patient NK cells for up to 21 days, even 
after retreatment (our unpublished data). 
 
We anticipate that the novel FT516 cell product will overcome the limitations of our 
current NK cell product, specifically by displaying better activity associated with 
longer survival after infusion into the peritoneal cavity. We have data showing that 
within the peritoneal microenvironment, the surface expression of CD16a on NK 
cells is significantly decreased presumed from ADAM17 mediated cleavage. This 
is one possible reason for decreased NK cell cytotoxicity in ovarian cancer that 
can be overcome with the use of the non-cleavable FT516 cell product. CD16a cell 
surface levels are tightly regulated by ADAM17 (Wu 2019, Romee 2013, Wang Y 
2013, Jing 2015). We were the first to report that ADAM17 mediates this process 
by cleaving CD16a in a cis manner at a specific location proximal to the cell 
membrane. (Jing 2015) Though this is a normal process of immune homeostasis, 
it has been reported that NK cells in the tumor tissues of ovarian cancer patients 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 21 of 79 
CPRC #2020LS001 
 
have significantly reduced levels of CD16a (Figure 2) and impaired anti-tumor 
effector functions (Lai 1996, Patankar 2005, Belisle 2007, Felices 2017). 
 
4 Study Design 
This is a single center Phase I clinical trial of FT516 administered intraperitoneally (IP) 
once a week for 3 consecutive weeks for the treatment of recurrent gynecologic 
cancers. As this combination is a first in human study and the first intraperitoneal 
infusion of FT516, the safety of FT516 is confirmed prior to adding enoblituzumab as 
an intravenous infusion approximately 1 week prior to the 1st dose of FT516. Each 
dose of FT516 is followed directly by an IP infusion of interleukin-2 (IL-2) to facilitate 
natural killer (NK) cell survival. A short course of outpatient lymphodepletion 
chemotherapy (CY/FLU) is given prior to the 1st dose of FT516. 
 
FT516 is an off the shelf product comprised of allogeneic natural killer (NK) cells, 
expressing high-affinity non-cleavable CD16 (FT516). Enoblituzumab is a monoclonal 
antibody that targets B7-H3 which is highly expressed on ovarian cancer.  
 
 
 
 
Figure 2. Percentage of CD16+ NK cells are significantly reduced in the peritoneal cavity 
compared to NK cells in the peripheral blood of ovarian cancer patients and in healthy 
patients. 
ASCITES
OV. PATIENT PBMC
NORMAL PBMC
0
20
40
60
80
100
CD16+ NK Cells %
ASCITES
OV. PATIENT PBMC
NORMAL PBMC
0
2000
4000
6000
8000
10000
CD16 MFI of NK Cells

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 22 of 79 
CPRC #2020LS001 
 
This study is conducted in two consecutive stages using the following treatment plan. 
In general:  
• 
All patients are assessed for Dose Limiting Toxicity (DLT) as defined in 
Section 7.5. The study switches to Stage 2 (CRM) at any point in Stage 1 
enrollment at the 1st DLT. 
• 
A minimum of 28 days must separate each patient cohort (the last patient enrolled 
in the cohort completes the DLT assessment period)  
• 
In multi-patient cohorts, a minimum of 14 days must separate the 1st and 2nd 
patient within a cohort.  
• 
Stage 1 Step 2 is not used if a DLT occurs during Stage 1 Step 1. 
• 
CRM is not used if no DLTs occur in Stage 1. 
 
Cohort 
Treatment Plan 
1 (start) 
IP FT516 monotherapy 9 x 10^7 cells/dose on Day 1, 8, and 15 
2 
IP FT516 monotherapy 3 x 10^8 cells/dose on Day 1, 8, and 15 
3 
IP FT516 monotherapy 9 x 10^8 cells/dose on Day 1, 8, and 15 
4 
Safe dose (MTD-1) from 1st 3 levels + IV enoblituzumab on Day -6  
5 
Highest dose (MTD) from 1st 3 levels + IV enoblituzumab on Day -6 
 
Stage 1 Step 1 uses a fast-track design (1 patient per Cohort) with a minimum of 28 
days between each patient until one of the following:  
 The 1st occurrence of a pre-defined adverse event within 28 days of the cell 
infusion (defined as Grade 3 abdominal pain for > 48 hours despite standard 
analgesics or Grade 3 infusion related reaction) at which point the study moves 
to Step 2 and the cohort size increases from 1 to 3 patients with 2 additional 
patients added to the current cohort. Escalation in Step 2 continues until the 1st 
DLT event at which point Stage 2 (CRM) is activated. If Cohort 5 is completed 
with 10 patients enrolled at the MTD without a DLT, Stage 2 (CRM) is not used. 
 The 1st occurrence of a DLT at which point the study moves directly to Stage 2 
(CRM) as detailed below and Step 2 is not used. 
 Cohort 5 is completed without a pre-defined AE or a DLT – neither Step 2 nor 
Stage 2 is used if a total of 10 patients are enrolled in Cohort 5 to complete the 
study. 
 
Stage 2 is initiated at the 1st DLT (as defined in Schema and in Section 7.5). The 
study design changes to the continual reassessment method (CRM). Enrollment 
occurs in cohorts of three with a minimum of 14 days between the 1st and 2nd patient. 
Each new cohort of three patients are sequentially assigned to the most appropriate 
dose by the study statistician based on the updated toxicity probabilities once the 3rd 
patient in a cohort reaches Day 28 (end of DLT period). The MTD will be identified by 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 23 of 79 
CPRC #2020LS001 
 
the minimum of the following criteria: (1) the total Stage 2 sample size of 25 is 
exhausted, (2) 10 consecutive patients are enrolled at the same dose plan or (3) the 
probability that the next 5 patients will be allocated to the same dose plan, based on 
the current estimate of the probability of toxicity, exceeds 90%. 
 
For study endpoints, follow-up continues until disease progression and then for 
survival only for 1 year from the 1st dose of FT516. 
 
After 1 year, follow-up will transfer to a separate long-term follow-up (LTFU) study to 
continue the FDA’s required 15 year follow-up after treatment with a genetically 
modified cell therapy. A separate consent is required for the LTFU study. 
 
5 Patient Selection 
Study entry is open to all adult women regardless of race or ethnic background. While 
there will be every effort to seek out and include minority patients, the patient 
population is expected to be no different than that of other gynecological cancer 
studies at the University of Minnesota and other participating institutions. 
5.1 Inclusion Criteria 
5.1.1 Recurrent epithelial ovarian cancer, fallopian tube, or primary peritoneal 
cancer meeting one of the following minimal prior treatment requirement 
(no limit to the maximum number of prior treatments): 
 Platinum Resistant: may receive FT516 as 2nd line (as 1st salvage 
therapy) with platinum resistant is defined as disease that has 
responded to initial chemotherapy but demonstrates recurrence within a 
relatively short period of time (< 6 months) following the completion of 
treatment. 
 Platinum Sensitive: may receive FT516 as 3rd line therapy (as 2nd 
salvage therapy) with platinum sensitive is defined as the recurrence of 
active disease in a patient who has achieved a documented response 
to initial platinum-based treatment and has been off therapy for an 
extended period of time (≥ 6 months). 
 
5.1.2 Measurable disease per modified Response Evaluation Criteria in Solid 
Tumors, v1.1 (iRECIST - refer to Appendix II) within the abdomen and 
pelvis assess within 42 days of the 1st FT516 infusion. Extra-peritoneal 
disease is permitted; however each lesion must be < 5 cm at the largest 
diameter. 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 24 of 79 
CPRC #2020LS001 
 
5.1.3 At least 18 years of age 
 
5.1.4 GOG Performance Status 0, 1, or 2 (refer to Appendix I) 
 
5.1.5 Adequate organ function within 14 days of study registration (28 days for 
pulmonary and cardiac) defined as: 
 Hematologic: platelets ≥ 75,000 x 109/L and hemoglobin ≥ 9 g/dL, 
unsupported by transfusions; absolute neutrophil count (ANC) ≥ 1000 x 
109/L, unsupported by G-CSF or granulocytes 
 Creatinine: Estimated glomerular filtration rate (eGFR) ≥ 60 
mL/min/1.73m2 per current institutional calculation formula 
 Hepatic: AST and ALT ≤ 3 x upper limit of institutional normal 
 Pulmonary Function: Oxygen saturation ≥ 90% on room air; PFT’s 
required only if symptomatic or prior known impairment - must have 
pulmonary function >50% corrected DLCO and FEV1   
 Cardiac Function: LVEF ≥ 40% by echocardiography, MUGA, or cardiac 
MRI; no clinically significant cardiovascular disease including any of the 
following: stroke or myocardial infarction within 6 months prior to first 
study treatment; unstable angina or congestive heart failure of New York 
Heart Association Grade 2 or higher (Appendix I) 
 
5.1.6 Agrees to the placement of an intraperitoneal catheter before the 1st dose 
of study directed drug (chemotherapy or enoblituzumab - Cohort 4 and 5) 
and remains in place through Day 36 or longer if retreatment is planned 
 
5.1.7 Agrees to undergo a tumor biopsy if feasible at the time the catheter is 
placed and removed – Accessible tumor for biopsy is not required for 
eligibility. 
 
5.1.8 Washout period of at least 14 days after any standard of care tumor 
directed therapy prior to the first dose of investigational product (FT516 for 
Levels 1-3 or enoblituzumab for Levels 4-5)  
 
5.1.9 If history of brain metastases must be stable for at least 3 months after 
treatment – A brain CT scan or MRI is only be required in subjects with 
known brain metastases at the time of enrollment or in subjects with clinical 
signs or symptoms suggestive of brain metastases 
 
5.1.10 Must agree to and sign the consent for the companion Long-Term Follow-
Up study (CPRC #2020LS072) to fulfill the FDA required 15 years of follow-
up for a genetically modified cell product 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 25 of 79 
CPRC #2020LS001 
 
 
5.1.11 Voluntary written consent prior to the performance of any research related 
procedures 
5.2 Exclusion Criteria 
5.2.1 Pregnant or breastfeeding or planning on becoming pregnant in the next 6 
months. Woman of childbearing potential who still have a uterus and 
ovaries, must agree to use at effective contraception and must have a 
negative pregnancy test within 14 days of study enrollment.  
 
5.2.2 Any known condition that requires systemic immunosuppressive therapy 
(> 5mg prednisone daily or equivalent) during the FT516 dosing period (3 
days before the 1st dose through 14 days after the last dose) – topical and 
inhaled steroids are permitted. 
 
5.2.3 Active autoimmune disease requiring systemic immunosuppressive 
therapy 
 
5.2.4 History of severe asthma and currently on chronic systemic medications 
(mild asthma requiring inhaled steroids only is eligible) 
 
5.2.5 Uncontrolled bacterial, fungal or viral infections with progression of clinical 
symptoms despite therapy 
 
5.2.6 Receipt of any investigational agent within 28 days prior to the first dose of 
investigational product (FT516 for Levels 1-3 or enoblituzumab for 
Levels 4-5) 
 
5.2.7 Live vaccine <6 weeks prior to start of lympho-conditioning 
 
5.2.8 Known allergy to the following FT516 components: albumin (human) or 
DMSO 
 
5.2.9 Any history of prior enoblituzumab administration 
 
5.2.10 Known history of HIV positivity or active hepatitis C or B - chronic 
asymptomatic viral hepatitis is allowed  
 
 
5.2.11 Presence of any medical or social issues that are likely to interfere with 
study conduct or may cause increased risk to patient 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 26 of 79 
CPRC #2020LS001 
 
6 Patient Screening and Study Enrollment  
6.1 Registration with the Masonic Cancer Center Clinical Trials Office 
Any patient who is consented is to be entered in OnCore by the site Study 
Coordinator or designee.  
 
If a patient is consented but is not enrolled in the study treatment (i.e. is found to 
be ineligible based on pre-transplant inclusion/exclusion criteria), the patient’s 
record is updated in OnCore as a screen failure and reason for exclusion recorded.  
6.2 Patient Enrollment and Cohort Assignment 
To be eligible for study treatment, the patient must sign the treatment consent and 
meet each inclusion criteria and none of the exclusion criteria on the eligibility 
checklist based on an eligibility assessment documented in the patient’s medical 
record. 
 
Up to 5 patient cohorts of FT-516 (with enoblituzumab in Cohort 4 and 5) are tested 
in this study. The patient is assigned to the currently enrolling cohort once eligibility 
is confirmed. 
6.3 Patient Re-Treatment with FT516 
If a patient achieves an initial response (iCR, iPR, iSD) at the Day 36 
reassessment, she may be eligible to repeat her assigned study treatment 
(CY/FLU lymphodepletion and 3 weekly doses of FT516/IL-2). If the patient initially 
was assigned to Cohort 4 or 5, it must be coordinated with the 3rd dose of 
enoblituzumab.  
 
If a patient achieves iUPD at the Day 36 reassessment, they will be given the 
option of keeping their IP catheter in place, re-scanning in 4 weeks, and if they 
have attained iSD, iPR, or iCR at that time, they may be eligible to repeat their 
assigned study treatment. If a patient achieves iUPD or iCPD at the re-scan, they 
will not be eligible for retreatment.    
 
A patient may be considered for retreatment if the following criteria is met (in 
addition to at least stable disease based on iRECIST): 
 The patient did not experience unacceptable toxicity (experienced DLT 
equivalent toxicity) or toxicity that caused a dose to be skipped during the 
first course of FT516. 
 All adverse events have resolved to ≤ Grade 1 or baseline, whichever is 
higher. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 27 of 79 
CPRC #2020LS001 
 
 No decline in GOG performance status from baseline. 
 The patient signs a re-treatment consent. 
 
After confirmation of eligibility and signing of a re-treatment consent, the patient 
will be registered to the re-treatment study (2020LS001R) in OnCore releasing a 
new study calendar. Retreatment will have no effect on the primary and secondary 
analysis; however, adverse events are documented and reported per Section 10. 
Study endpoints will remain at 6 months and 12 months from 1st FT516 infusion. 
6.4 Patients Who Do Not Begin Study Treatment 
If a patient is registered to the study and is later found not able to begin study 
treatment (beginning with the 1st dose FT516 for Cohorts1-3 or 1st dose of 
enoblituzumab for Cohorts 4 and 5), the patient will be removed from the study 
and treated at the physician’s discretion. The study staff will update OnCore with 
the patient’s non-treatment status. The reason for removal from study must be 
clearly indicated in OnCore. The patient will be replaced to complete enrollment. 
7 Treatment Plan 
In order to provide optimal patient care and to account for individual medical 
conditions, investigator discretion may be used in the prescribing of all supportive care 
drug therapy (i.e. acetaminophen, diphenhydramine, antimicrobials, etc.).  
 
There is some flexibility in the timing of the treatment as long as the ordering of the 
treatment is maintained and a minimum of 48 hours separates the last dose of 
fludarabine and the 1st FT516 infusion. 
7.1 Peritoneal Catheter Placement (Day – 6 or earlier) 
Successful placement of the IP catheter is required before proceeding with the 
lymphodepleting chemotherapy. If an IP catheter cannot be placed, the patient will 
be taken off study and replaced. 
 
The peritoneal site where the catheter is to penetrate the peritoneum is identified 
under direct vision by Interventional Radiology. It is important to enter the 
peritoneal cavity under direct vision because a previous staging laparotomy for 
ovarian cancer is likely to have resulted in adhesion formation, particularly between 
bowel and anterior abdominal wall. The catheter insertion site through the 
peritoneum must be separate from other incisions.   
 
There is a risk for spread of cancer cells that are located within the peritoneum to 
surrounding tissues such as the abdominal wall.  This risk is associated with the 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 28 of 79 
CPRC #2020LS001 
 
penetration of the abdominal cavity during the IP catheter placement as it exposes 
new surfaces for the cancer cells to attach.  Implantation of malignant cells within 
surgical incisions and along biopsy needle and drainage catheter tracts is a 
recognized mechanism for the dissemination of cancer.  In one review published 
of 255 patients with epithelial ovarian carcinoma, Dauplat et al. (Dauplat, et al. 
1987) included nine cases (3.5%) with skin metastases, one of which occurred at 
the site of a catheter used for intraperitoneal chemotherapy. Kohler et al. (Kohler, 
et al. 1991) described two patients who were treated with intraperitoneal 
administration and subsequently developed abdominal wall metastases. In one 
case the lesions were at the site of previous surgical incisions. In the other, 
metastasis occurred at the former site of the peritoneal access catheter which had 
been removed after therapy 2.5 years earlier.  Implantation metastases is a 
potential hazard of all invasive procedures in the case of malignancy. Although 
thought to be a rare event, placement of a peritoneal access catheter in ovarian 
cancer may be a risk for seeding tumor cells. 
 
The baseline research related peritoneal cell collection (ascites or intraperitoneal 
washing) and a tumor biopsy, if feasible will be done at placement (and removal). 
Refer to Section 9.2.1 and Section 9.2.2. 
 
The catheter will remain in place until at least Day 36 for peritoneal IP cell collection 
and biopsy or longer, if the patient agrees to and is eligible for a 2nd treatment 
course. 
7.2 Enoblituzumab (Day -6 then Day 22 and every 21 Days thereafter) - Cohort 4 
and 5 only 
Enoblituzumab 15 mg/kg is given as an intravenous infusion over 120 minutes (±15 
minutes) using a commercially available pump. A window of ±2 days is permitted. 
The dose of enoblituzumab initially is calculated based on the patient’s actual 
weight. Treatment is administered in the outpatient clinic.  
 
Obtain vital signs (temperature, blood pressure, respiration and pulse) upon 
arrival, within 15 minutes of starting the enoblituzumab, every 15 minutes (± 5 
minutes for the first hour of the infusion, every 30 minutes (±5 minutes) thereafter 
until infusion end, upon discontinuing infusion, and before the patient is discharged 
from the clinic. 
 
The 1st dose of enoblituzumab is given Day -6 (±2 days) and at least 1 day before 
the start of CY/FLU preparative regimen. 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 29 of 79 
CPRC #2020LS001 
 
Subsequent doses of enoblituzumab are given every 21 days (±2 days) starting on 
Day 22 using the 1st dose of FT516 as Day 1. Treatment may continue until disease 
progression or unacceptable side effects. 
 
If a patient is eligible for re-treatment per Section 6.3, the 3rd dose of enoblituzumab 
(around Day 43) serves as the anchor for CY/FLU and FT-516/IL-2 administration. 
7.2.1 Pre-Medications and Prophylaxis Guidelines  
Required prior to the first infusion of enoblituzumab: 
 Acetaminophen 650-1000 mg orally (PO) or ibuprofen 400 mg PO, or 
equivalent 
 Diphenhydramine 50 mg PO or IV or equivalent H1 antagonist 
 Ranitidine 300 mg PO or IV or equivalent H2 antagonist 
 Dexamethasone 10-20 mg IV. 
 
No pre-infusion prophylactic steroids administration is required for subsequent 
infusions. Non-steroidal pre-medications may be administered prior to the 
subsequent infusion, if warranted.  
 
Antiemetic therapy including but not limited to neurokinin 1 (NK1) receptor 
antagonists, 
serotonin 
(5HT3) 
receptor 
antagonists, 
benzodiazepines, 
antihistamines, cannabinoids, cholinergic antagonists and dopamine receptor 
antagonists may be administered according to good clinical practice and local 
guidelines.  
If the patient experiences a ≥ Grade 2 infusion related reaction with the first infusion 
refer to the recommended pre-medications found in the Grade 2 Infusion Related 
Reaction in Section 7.2.2. At Day 22 and beyond steroid use is permitted as a pre-
med in the setting of a recurrent Grade 2 or Grade 3 infusion related reaction.  
7.2.2 
Management of Observed Infusion Related Reactions 
Grade 3 or greater infusion related reactions are reportable as a DLT (if within 28 
days of the 1st FT516 infusion), AESIs and/or SAEs, as applicable per Section 9.2. 
The following are treatment guidelines (which may be modified as needed by the 
Investigator according to the best practices of medicine) for infusion reactions: 
Grade 1 Infusion Related Reaction: 
 
Slow the infusion rate by 50%. 
 
Monitor the patient for worsening of condition. 
 
Continue rate at 50% reduction and increase dose rate to the original rate 
by doubling the infusion rate after 30 minutes, as tolerated to the initial rate. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 30 of 79 
CPRC #2020LS001 
 
Consideration can be given to beginning subsequent infusions at 50% rate 
and increasing as tolerated. 
 
The following prophylactic pre-infusion medications are recommended prior 
to future infusions of study treatment for patients who experience Grade 1 
infusion reactions: 
o Diphenhydramine 25 to 50 mg (or equivalent) PO/IV. 
o Acetaminophen 650 mg PO and/or ibuprofen 400 mg PO, or equivalent, 
at least 30 minutes before additional study drug administrations. 
o Ranitidine 300 mg PO or 50 mg IV or equivalent H2 antagonist before 
additional study drug administrations. 
  
Grade 2 Infusion Related Reaction: 
 Stop the infusion. 
o Administer diphenhydramine hydrochloride 25 to 50 mg IV. 
o Acetaminophen 650 mg PO or ibuprofen 400 mg PO, or equivalent, for fever. 
o Oxygen and bronchodilators for mild bronchospasm. 
 Resume the infusion at 50% of the prior rate once the infusion reaction has 
resolved or decreased to Grade 1. The rate may then be escalated to the 
original rate after 30 minutes, as tolerated. Consideration can be given to 
beginning all subsequent infusions at 50% rate and increasing as tolerated. 
 Monitor for worsening condition. If symptoms recur, discontinue the infusion; 
no further study drug will be administered at that visit. 
 Prophylactic pre-infusion medications should be given prior to subsequent 
infusions of study treatment.  
o Patients who experience Grade 2 infusion reaction, for subsequent doses of 
study treatment, pre-medicate with diphenhydramine hydrochloride 25 to 50 
mg IV/PO and acetaminophen 650 mg PO and/or ibuprofen 400 mg PO (or 
equivalent) at least 30 minutes before additional study drug administrations.  
o For patients with Grade 2 infusion reactions, despite premedication with 
diphenhydramine and acetaminophen and/or ibuprofen (or equivalent), 
corticosteroids (10 to 20 mg dexamethasone IV or equivalent) may be added 
to the premedication regimen for the next dosing of study treatment. Reduce 
corticosteroid dosing by 50% for the subsequent dose and hold thereafter, if 
there are no reactions. 
  
Grade 3 Infusion Related Reaction: 
 
STOP THE INFUSION AND DISCONNECT THE INFUSION TUBING FROM 
THE PATIENT. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 31 of 79 
CPRC #2020LS001 
 
 
TO AVOID EXACERBATION OF INFUSION REACTION OR CRS: DO NOT 
FLUSH THE TUBING – ASPIRATE RESIDUAL DRUG FROM THE PORT 
LUMEN. 
 
Administer diphenhydramine hydrochloride 25 to 50 mg IV, dexamethasone 
20 mg IV (or equivalent), and other medications/treatment as medically 
indicated. Higher doses of corticosteroids (e.g., methylprednisolone 2 to 4 
mg/kg IV or the equivalent) may also be considered for acute management. 
 
Consider administering, tocilizumab (an IL6 receptor antagonist) 4 mg/kg IV. 
 
IV fluids, supplemental oxygen, H2 blockers such as ranitidine and 
bronchodilators should be considered, as appropriate. 
 
If the Grade 3 infusion reaction occurs with any study treatment, it will be 
discontinued for that day.  
o If symptoms have resolved to baseline within 12 hours, study treatment 
may be infused at the next scheduled dose, with a 50% reduction of 
infusion rate. In addition, patients should be pre-medicated for this re-
challenge and for any subsequent doses of study treatment with the 
following: diphenhydramine hydrochloride 25 to 50 mg IV, acetaminophen 
650 mg PO and/or ibuprofen 400 mg PO (or equivalent); corticosteroids 
should be considered as well (dexamethasone 10 to 20 mg IV or 
equivalent). Reduce corticosteroid dosing by 50% for the subsequent dose 
and hold thereafter, if there are no reactions. 
o Patients who have a Grade 3 infusion reaction that does not resolve within 
12 hours despite medical management should be discontinued from study 
treatment. 
 
Patients who experience a second Grade 3 infusion reaction at the time of re 
challenge of study treatment (the same study treatment for which the first 
Grade 3 infusion reaction was seen) will permanently discontinue study 
treatment. 
 
Grade 4 Infusion Related Reaction: 
 
STOP THE INFUSION AND DISCONNECT THE INFUSION TUBING FROM 
THE PATIENT. 
 
TO AVOID EXACERBATION OF INFUSION REACTION OR CRS: DO NOT 
FLUSH THE TUBING. ASPIRATE RESIDUAL DRUG FROM THE PORT 
LUMEN 
 
Administer diphenhydramine hydrochloride 50 mg IV, dexamethasone 20 mg 
IV (or higher doses of steroids, e.g., methylprednisolone 2 to 4 mg/kg IV or the 
equivalent, as considered appropriate). 
 
Consider administering, tocilizumab (an IL6 receptor antagonist) 4 mg/kg IV. 
 
Give epinephrine or bronchodilators as indicated. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 32 of 79 
CPRC #2020LS001 
 
 
Support ventilation and blood pressure as indicated. 
 
Patients who have a Grade 4 infusion reaction will permanently discontinue 
study treatment. 
7.3 Preparative Regimen (Day -5 and Day -4) 
A lymphodepleting regimen of fludarabine and cyclophosphamide is given in the 
outpatient clinic on two consecutive days. If there is unresolved toxicity associated 
with the enoblituzumab, treatment may be delayed; however, the second day of 
CY/FLU must be no later than Day -2 to ensure a minimum of a 48 hour wash-out 
period prior to the FT516 cell infusion.  
 
The administration of the preparative regimen will follow the institutional dosing 
guidelines. Dose and/or schedule adjustments consistent with the standard of care 
may be made on an individual patient basis as needed for safety.  
 
Fludarabine 25 mg/m2 is administered as a 1 hour intravenous (IV) infusion per 
institutional guidelines once a day on 2 consecutive days. 
 
Cyclophosphamide 300 mg/m2 is administered as a 2 hour intravenous infusion 
per institutional guidelines once a day on the same 2 days fludarabine is given.  
 
Cyclophosphamide dosing is calculated based on ABW (Actual Body Weight) 
unless ABW is >150% of the IBW (Ideal Body Weight). 
Adjusted body weight = IBW + 0.5(ABW-IBW). 
 
 
Cyclophosphamide associated hydration will be given according to recommended 
institutional standards. 
7.4 FT516 and IL-2 (Day 1, Day 8, and Day 15) 
A minimum of 48 hours must separate the last dose of fludarabine and the 1st 
dose of FT516. The 1st dose of FT516 may be delayed for up to 7 days after the 
last dose of fludarabine if the study physician feels a delay is in the best interest of 
the patient. The 1st dose of FT516 equals Day 1. 
 
A ± 1 day window is permitted for subsequent infusions to accommodate 
scheduling issues. 
 
Decision to Treat on Day of Planned FT516: Three weekly doses of FT516 are 
planned; however, if on the day of treatment, the study physician feels it is not in 
the best interest of the patient to receive treatment, the FT516/IL-2 may be: 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 33 of 79 
CPRC #2020LS001 
 
 Delayed for up to 48 hours adjusting future time points to maintain timing 
OR 
 Skipped and the patient scheduled for the next planned visit. Skipped 
dose(s) are not made up. 
 
Pre-medications: Prior to the administration of FT516 and IL-2 and 4 hours later, 
patients should be given acetaminophen 650 mg orally and diphenhydramine 25 
mg orally. Corticosteroids should not be used as pre-medication for FT516.  
 
If a large amount of ascites is present it will be drained prior to instillation of the 
FT516 and IL-2. Refer to Section 9.2.1 regarding submitting ascites, if present, for 
research related testing.  
 
FT516 Infusion guidelines: FT516 is provided in one or more cryopreserved bags 
depending on the patient’s assigned FT516 cell dose (Level 1: 9 x 107 cells, 
Level 2: 3 x 108 cells, or Level 3: 9 x 108 cells). Thawing of the bag(s) is according 
to the FT516 Storage, Handling, and Administration Guidance.  
 
FT516 must be administered using an IV administration set without an in line filter 
(filter is not required for IP administration). FT516 is administered as an IP infusion 
via gravity.  
 
Each bag and tubing then will be flushed with 50 cc of room temperature normal 
saline. Prior to the IL-2, flush the line a final time with 50 cc of D5W at room 
temperature. 
IL-2 administration: IL-2 at 6 MIU (3 MIU/m2 if patient weight is <45 kg) is 
administered IP in 50 cc of room temperature D5W via peritoneal catheter directly 
after the FT-516 infusion is completed. Immediately following the IL-2, an 
additional 100 cc D5W flush is infused into the peritoneal cavity through the 
peritoneal catheter as rapidly as possible.  
 
After the 100 cc D5W flush, the patient is asked to change position at 15-minute 
intervals for two hours to ensure adequate intra-abdominal distribution. No attempt 
will be made to retrieve the infusate.  
 
Vital Signs include oral temperature, systolic and diastolic blood pressure, heart 
rate, respiratory, and pulse oximetry. On days of FT516 administration, collect as 
follows: within 15 minutes prior to the infusion of FT516, at 10 (±5) minutes during 
infusion, and every 15 (±5) minutes for 1 hour following the end of infusion of the 
last administered bag of FT516 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 34 of 79 
CPRC #2020LS001 
 
 
Monitoring for Acute Adverse Events of FT516: 
In our previous study of intraperitoneal (IP) Fate NK100 and IL-2 minimal toxicity 
was seen and primarily was related to abdominal pain/cramping.  
 
Patients are monitored for infusion related reactions. If an infusion reaction of any 
grade occurs do not give any remaining bags of cells (if relevant). Refer to Table 
1 for management guidelines based on infusion related reaction CTCAE v5 
grading. 
 
Dose modification guidelines for IL-2 related toxicity:  
Grade 3 adverse event: if the toxicity resolves to grade 2 or better within 48 hours, 
the IL-2 can be resumed at a reduced dose (4 million units or 2 million units/m2 if 
< 45 kg). If after a dose reduction the same toxicity persists, worsens, or recurs, 
the IL-2 must be permanently discontinued. 
Grade 4 adverse event: permanently discontinue IL-2 
7.5 Monitoring for Dose Limiting Toxicities 
All patients are monitored for dose limiting toxicities for 28 days after the 1st FT516 
infusion. 
 
In addition, during the initial fast-track dose escalation (Stage 1, Step 1), patients 
also are monitored under a separate set of criteria for abdominal pain and infusion 
related reaction for 28 days post infusion as defined in the Schema and Study 
Design. The 1st occurrence of an event triggers a switch from enrolling 1 patient 
per cohort to 3 patients per level (Stage 1, Step 2) and monitoring for dose limiting 
toxicity. If in Stage 1, Step 1, a patient experiences a DLT, enrollment moves 
directly to Stage 2 using CRM. 
 
DLT is defined as any treatment emergent toxicity at least possibly related to the 
study treatment meeting one of the following criteria based on CTCAE v5 within 
28 days (14 days for ascites) of the 1st FT516 infusion (for Cohort 4 and 5, DLT 
assessment starts with enoblituzumab and continues for 28 days after 1st FT516): 
 Grade 3 organ toxicity (pulmonary, hepatic, renal, or neurologic) not pre-existing 
and lasting more than 72 hours  
 Any non-hematologic Grade 4 or 5 toxicity 
 Neutrophil count decreased ≥ Grade 4 that persists at Day 28 despite use of 
growth factor support 
 Grade 3 abdominal pain lasting more than 4 consecutive days and not controlled 
by standard analgesics 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 35 of 79 
CPRC #2020LS001 
 
 Grade 3 or greater ascites within 14 days after FT516 administration in patients 
who had no ascites or Grade 1 ascites at enrollment and is not attributable to 
disease progression 
7.6 
Supportive Care 
Throughout the study, the investigator may prescribe any concomitant medications 
or treatment deemed necessary to provide adequate supportive care. Supportive 
care may include antibiotics, anti-fungals, analgesics, transfusions, growth factors.  
7.7 
General Concomitant Medication Guidelines 
Because they may inhibit NK cell function, systemic corticosteroids should be 
avoided 3 days before the 1st dose of FT516 through 14 days after the last FT516 
infusion unless absolutely required. Dexamethasone as premedication for 
cyclophosphamide and fludarabine may be administered per the USPI.   
 
Corticosteroids should not be used as pre-medication for FT516. 
 
Beta-blockers and other anti-hypertensives may potentiate hypotension 
associated with IL-2, especially if the patient is not well hydrated.  
7.8 Duration of FT516 / IL-2 Treatment and Possible Retreatment 
Treatment with FT516 and IL-2 consists of a single treatment course of 3 weekly 
doses on Day 1, Day 8, and Day 15 (with 2 doses of enoblituzumab if assigned to 
Cohort 4 or 5).  
 
If a patient achieves an initial response (iCR, iPR, iSD) at the 1st disease re-
assessment around Day 36, she may be eligible to repeat the treatment at her 
same FT516 cohort provided the criteria in Section 6.3 is met. If a patient achieves 
iUPD at the Day 36 reassessment, they will be given the option of keeping their IP 
catheter in place, re-scanning in 4 weeks, and if they have attained iSD, iPR, or 
iCR at that time, they may be eligible to repeat their assigned study treatment. If a 
patient achieves iUPD or iCPD at the re-scan, they will not be eligible for 
retreatment.    
 
Retreatment will have no effect on the primary and secondary analysis; however, 
adverse events are documented and reported per Section 10. Study endpoints will 
remain 6 months and 12 months from 1st FT516 infusion. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 36 of 79 
CPRC #2020LS001 
 
7.9 Duration of Enoblituzumab (COHORT 4 or 5 ONLY) 
Enoblituzumab may continue every 3 weeks from Day 22 until disease progression 
and/or unacceptable toxicity or patient refusal. If a patient is eligible for retreatment 
with FT516/IL-2 this would occur in association with the 3rd dose of enoblituzumab. 
7.10 Duration of Study Participation 
Patients will be followed for disease response until disease progression/relapse 
and then survival only for 12 months from the 1st FT516 infusion unless: 
 consent is withdrawn  
 patient did not receive FT516 – if a patient is not evaluable, follow only until the 
resolution or stabilization of treatment related toxicity 
 new anti-cancer treatment is started (follow for survival only) 
 patient is discharged to hospice (terminal) care    
 
If applicable, enoblituzumab may continue every 3 weeks beyond 12 months in the 
absence of disease progression and unacceptable toxicity. 
 
Any patient receiving at least 1 dose of FT516 must be followed for up to 15 years 
for late effects and survival. After the visit at 12 months from the FT516 the patient 
transfers to the long-term follow-up protocol (CPRC# 2020LS072) separate 
consent required at enrollment into this treatment study) and continue to be 
followed for safety, anti-tumor activity, and survival for up to 15 years from the 1st 
FT516 infusion. 
 
8 Management of Selected Expected Toxicities Associated with 
Enoblituzumab and/or FT516/IL-2 Administration 
See Appendix III for expected toxicities of the lymphodepleting regimen and IL-2. 
8.1 Known Infusion Related Reaction (IRR) to Enoblituzumab (Cohort 4 and 5) 
Refer to Section 7.2.2 for the management of enoblituzumab related infusion 
reaction. 
 
To date, the most important safety risk that has been identified with enoblituzumab 
is infusion-related reactions (IRR), including reactions known as cytokine release 
syndrome (CRS) due to the release of small proteins (cytokines) from the cells. 
IRRs are generally temporary effects due to a drug that may occur during or shortly 
after infusion of the drug.  
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 37 of 79 
CPRC #2020LS001 
 
Signs and symptoms of an infusion-related reaction may include fever, chills, 
nausea, vomiting, headache, muscle stiffness, rash, itching, low blood pressure, 
and difficulty breathing. IRRs can be life threatening and, in rare cases, may cause 
death. For all adult studies, IRRs (including CRS) have occurred in a total of 47.6 % 
(between 4-5 out of 10) participants receiving treatment with enoblituzumab. 
 
Most of the IRRs observed in patients receiving enoblituzumab have been mild to 
moderate in severity. However, five patients receiving enoblituzumab alone and 
twelve patients on enoblituzumab in combination with checkpoint blockade have 
had severe IRRs. Two participants experienced IRR/CRS that were considered 
life-threatening. These patients, some of whom were hospitalized for these 
reactions, recovered after receiving treatment with steroids, antihistamines and 
intravenous fluids. Three patients discontinued from the treatment after 
experiencing an IRR. Based on these known IRR, a management plan has been 
developed by MacroGenics, the drug manufacturer. 
8.2 Infusion Related Reaction Secondary to the Infusion of FT516 
In our previous study of intraperitoneal (IP infusion) Fate NK100 and IL-2 minimal 
toxicity was seen and primarily was related to abdominal pain/cramping.  
 
Patients are monitored for acute infusion related reactions associated with 
intravenous infusions including rigors and chills, rash, urticaria, hypotension, 
dyspnea, and angioedema during and after IP infusion.   
 
Patients should be monitored for the occurrence of hypotension, dyspnea, and 
angioedema during and immediately after the infusion. Appropriate medical care 
should be instituted as per the respective current local prescribing information or 
standard institutional practices. Because they may inhibit NK cell function, 
systemic corticosteroids should be avoided unless absolutely required for 
management of acute allergic/infusion reactions, as determined by the 
Investigator.  
 
Refer to Table 1 for management guidelines based on infusion related reaction 
CTCAE v5 grading. 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 38 of 79 
CPRC #2020LS001 
 
 
 
8.3 DMSO-Related Risks 
FT516 is formulated in DMSO to enable cryopreservation. Intravenous DMSO side 
effects and symptoms are generally associated with histamine release and include 
coughing, flushing, rash, chest tightness and wheezing, nausea and vomiting, and 
cardiovascular instability. However, due to the small cell bag volume (~28 ml) and 
intraperitoneal infusion, a reaction to DMSO is not expected. 
8.4 Infection  
FT516 is cell therapy of human origin. During processing, the cells are in contact 
with reagents of animal origin, and FT516 has a final formulation which contains 
albumin (human). As with any product of human and/or animal origin, transmission 
of infectious disease and/or disease agents by known or unknown agents may 
Table 1: Recommended Guidelines for the Management of Acute Allergic/Infusion Reaction with FT516 Administration 
Grade 
Management 
Any Grade 
 Interrupt FT516 administration. 
 Manage symptoms, e.g., with antihistamines, antipyretics and analgesics, according to standard 
institutional practice standards 
Grade 3 
 Resume FT516 administration only upon complete resolution of the infusion-related reaction and 
at the discretion of the Investigator.  Given that FT516 administration may involve single or 
multiple bags depending on the total planned dose and accounting for the stability of FT516 
post-thaw, FT516 administration may continue following resolution of Grade 3 infusion-related 
reactions as follows: 
If single-bag FT516 dosing: 
 No additional FT516 may be administered. 
 The volume of FT516 administered prior to the infusion-related reaction must be documented; 
retain any remaining product and contact the Sponsor for further instruction. 
 Additional bags may not be administered to make up for FT516 that was not administered from 
the bag during which the infusion-related reaction occurred. 
If multiple-bag FT516 dosing: 
− 
The volume of FT516 administered from the bag during which the infusion-related reaction 
occurred must be documented; retain any remaining product from the bag and contact the 
Sponsor for further instruction. 
− 
If dosing with additional FT516 bags was planned, they may be thawed and administered. 
− 
Additional bags beyond what was originally planned may not be administered to make up for 
FT516 that was not administered from the bag during which the infusion-related reaction 
occurred. 
Grade 
Management 
Grade 4 
 Stop FT516 administration.  Do not restart. 
The volume of FT516 administered prior to the infusion-related reaction must be documented; 
retain any remaining product and contact the Sponsor for further instructions. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 39 of 79 
CPRC #2020LS001 
 
occur. FT516 has been extensively tested to minimize the potential risk of disease 
transmission. However, these measures do not completely eliminate the risk. For 
some infectious agents, there are no routine tests to predict or prevent disease 
transmission. 
8.5 IL-2 
IL-2 when given subcutaneously is associated with constitutional symptoms (flu-
like symptoms) which may be dose limiting. IL-2 related toxicities associated with 
subcutaneous IL-2 are found in Appendix III. 
 
In this study IL-2 is administered directly after FT516. Prior to administration of 
FT516 and 4 hours later, it is recommend patients are given acetaminophen 650 
mg orally and diphenhydramine 25 mg orally to reduce or avoid expected toxicities 
of both FT516 and IL-2.  
 
In a study of women with platinum resistant or refractory ovarian cancer the 
administration of single agent IL-2 weekly at dose higher than used in this study 
was generally well tolerated. Grade 1 and 2 constitutional symptoms (flu-like 
symptoms, GI and neurological) were most common, but controlled with 
medication and not requiring dose reduction (Vlad). 
8.6 Cytokine Release Syndrome (CRS) or CRS-Like Symptoms 
While CRS is a clearly defined syndrome in T cell therapy, it is not known to occur 
to the full extent in NK cell therapies. However, we have seen immune activation 
syndromes with other IL-15 products that include fever, CNS toxicities, and rash 
but without T cell mediated vascular collapse.  
If CRS is suspected, CRP and ferritin levels should be assessed locally, and a 
serum sample collected for an IL-6 level (if testing available at the treating 
institution). 
 
If indicated by the presence of medically significant symptoms and/or high IL-6 
levels or any symptoms requiring intervention, steroids are the first line of 
treatment. 
 
To consistently characterize its severity, CRS must be graded as outlined in the 
ASTCT CRS consensus grading system provided in Table 4 (Section 10). Because 
the signs and symptoms of CRS are not unique to CRS, other causes of fever, 
hypotension and/or hypoxia must be excluded. Notably, bacteremia and other 
severe infections have been reported concurrent with and even mistaken for CRS 
(Lee et al. 2019). 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 40 of 79 
CPRC #2020LS001 
 
If CRS occurs (e.g. a differential diagnosis is recorded in the institutional medical 
record), CRP and ferritin levels should be done three times weekly until the 
resolution of CRS per Section 8.1. In addition, a serum sample should be collected 
for an IL-6 level at the time of any change (increase or decrease) in the CRS grade. 
Because patients may be outpatients any missed collection time points will not be 
a protocol deviations. 
 
Management of CRS should follow the recommended management algorithm 
provided in Table 2 (Neelapu 2018) and/or institutional practice. 
 
Table 2: Recommendations for the Management of Cytokine Release Syndrome 
Grade 
Sign/Symptom Management 
Grade 1 
Fever or 
organ toxicity 
 Acetaminophen and hypothermia blanket for the treatment of fever 
 Ibuprofen can be used as second treatment option for fever, if not 
contraindicated 
 Assess for infection using blood and urine cultures, and chest 
radiography 
 Empiric broad‑spectrum antibiotics and filgrastim if neutropenic 
 Maintenance IV fluids for hydration 
 Symptomatic management of constitutional symptoms and organ 
toxicities 
 Consider tocilizumab 8 mg/kg a IV or siltuximab 11 mg/kg IV for 
persistent (lasting ≥3 days) and refractory fever 
Grade 2 
Hypotension 
 IV fluid bolus of 500–1,000 mL of normal saline 
 Can give a second IV fluid bolus if systolic blood pressure remains 
<90 mmHg 
 Tocilizumab 8 mg/kg a IV or siltuximab 11 mg/kg IV for the treatment of 
hypotension that is refractory to fluid boluses; up to 3 additional doses 
of tocilizumab may be administered, and the interval between 
consecutive doses should be at least 8 hours. 
 If hypotension persists after two fluid boluses and anti‑IL‑6 therapy, start 
vasopressors, consider transfer to ICU, obtain echocardiogram, and 
initiate other methods of hemodynamic monitoring 
 In subjects at high-risk b or if hypotension persists after 1–2 doses of 
anti‑IL‑6 therapy, dexamethasone can be used at 10 mg IV every 6 
hours 
 Manage fever and constitutional symptoms as in Grade 1 
Hypoxia 
 Supplemental oxygen 
 Tocilizumab or siltuximab ± corticosteroids and supportive care, as 
recommended for the management of hypotension 
Organ 
toxicity 
 Symptomatic management of organ toxicities, as per standard 
guidelines 
 Tocilizumab or siltuximab ± corticosteroids and supportive care, as 
indicated for hypotension 
 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 41 of 79 
CPRC #2020LS001 
 
Table 2: Recommendations for the Management of Cytokine Release Syndrome 
Grade 
Sign/Symptom Management 
Grade 3 
Hypotension 
 IV fluid boluses as needed, as recommended for the treatment of Grade 
2 CRS 
 Tocilizumab and siltuximab as recommended for Grade 2 CRS, if not 
administered previously 
 Vasopressors as needed 
 Transfer to ICU, obtain echocardiogram, and perform hemodynamic 
monitoring as in the management of Grade 2 CRS 
 Dexamethasone 10 mg IV every 6 hours; if refractory, increase to 20 mg 
IV every 6 hours 
 Manage fever and constitutional symptoms as indicated for Grade 1 
CRS 
Hypoxia 
 Supplemental oxygen including high‑flow oxygen delivery and 
non‑invasive positive pressure ventilation 
 Tocilizumab or siltuximab plus corticosteroids and supportive care, as 
described above 
Organ 
toxicity 
 Symptomatic management of organ toxicities as per standard guidelines 
 Tocilizumab or siltuximab plus corticosteroids and supportive care, as 
described above 
Grade 4 
Hypotension 
 IV fluids, anti‑IL‑6 therapy, vasopressors, and hemodynamic monitoring 
as defined for the management of Grade 3 CRS 
 Methylprednisolone 1 g/day IV 
 Manage fever and constitutional symptoms as in Grade 1 CRS 
Hypoxia 
 Mechanical ventilation 
 Tocilizumab or siltuximab plus corticosteroids and supportive care, as 
described above 
Organ 
toxicity 
 Symptomatic management of organ toxicities as per standard guidelines 
 Tocilizumab or siltuximab plus corticosteroids and supportive care, as 
described above 
CRS, cytokine release syndrome; ICU, intensive care unit; IV, intravenous.  
NOTE: All medication doses indicated are for adults.  
a 
Maximum amount of tocilizumab per dose is 800 mg.  
b 
High-risk subjects include those with bulky disease and those with comorbidities. 
Reference: Neelapu 2018, Actemra USPI 
8.7 Tumor Lysis Syndrome 
Tumor lysis syndrome (TLS) is a possible fatal risk associated with anti-tumor 
therapy. TLS symptoms include nausea, vomiting, diarrhea, muscle cramps or 
twitches, weakness, numbness or tingling, fatigue, decreased urination, irregular 
heart rate, restlessness, irritability, delirium, hallucinations, and seizures. TLS is 
comprised of abnormal lab changes that include hyperuricemia, hyperkalemia, 
hyperphosphatemia, and hypocalcemia. TLS has been reported to occur within 7 
days following chemotherapy across various solid tumor settings, with ten 
published reports of TLS cases in patients with gynecological cancer 
(Mirrakhimov 2014).  

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 42 of 79 
CPRC #2020LS001 
 
One case of fatal metabolic syndrome compatible with TLS was reported following 
NK cell therapy in a patient with ovarian cancer (Geller 2011) 5 days after receiving 
CY. Prophylaxis for and management of TLS should be done in accordance with 
standard institutional practice. 
8.8 Neurotoxicity  
While CNS toxicity is a clearly defined syndrome associated with T-cell-based 
therapies or with high-dose IL-2, it is rare and generally not believed to be a toxicity 
associated with NK cell therapies, including those given with IL-2 at these doses. 
Neurotoxicity was reported in one trial of adoptively transferred NK cells given with 
SC IL-15 but the mechanism of the toxicity was not well defined (Cooley et al. 
2019). Nervous system toxicities following CD19 CAR-T therapy is characterized 
by encephalopathy, confusion, delirium, aphasia, obtundation, and seizures 
(Kymriah USPI 2018; Yescarta USPI 2019). Cases of cerebral edema have also 
been reported (Brudno 2016). 
 
To consistently characterize its severity, neurotoxicity must be graded using the 
ASTCT guidelines for grading ICANS provided in Section 10 based on the Immune 
Effector Cell-Associated Encephalopathy (ICE) score and Table 3. Per Section 9 
an assessment is done prior to each FT516/IL-2 infusion, 2 to 4 hours later, and at 
the time of discharge if the post-infusion stay extends beyond 4 hours.  
Determinants of the ICE score are: 
 Orientation: Orientation to year, month, city, hospital: 1 point each for 
maximum of 4 points 
 Naming: Name 3 objects (e.g., point to clock, pen, button): 1 point each for 
maximum of 3 points 
 Following commands: (e.g., show me 2 fingers or close your eyes and stick 
out your tongue): 1 point 
 Writing: Ability to write a standard sentence (e.g., our national bird is the bald 
eagle): 1 point 
 Attention: Count backwards from 100 by ten: 1 point 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 43 of 79 
CPRC #2020LS001 
 
 
Table 3: ASTCT Immune Effector Cell-Associated Neurotoxicity Syndrome Grading a 
Neurotoxicity 
Domain  
Grade 1  
Grade 2  
Grade 3  
Grade 4  
ICE Score b  
7–9   
3–6  
0–2  
0 (subject is unarousable 
and unable to perform ICE.) 
Depressed level 
of 
consciousness c  
Awakens 
spontaneously 
Awakens to 
voice 
Awakens only to 
tactile stimulus 
Subjects is unarousable or 
requires vigorous or 
repetitive tactile stimuli to 
arouse. Stupor or coma. 
Seizure 
N/A 
N/A 
Any clinical seizure 
Focal/generalized 
that resolves rapidly; 
or Non-convulsive 
seizures on EEG that 
resolve with 
intervention 
Life-threatening prolonged 
seizure (>5 minutes); or 
Repetitive clinical or 
electrical seizures without 
return to baseline in 
between. 
Motor Findings d 
N/A 
N/A 
N/A 
Deep focal motor weakness 
such as hemiparesis or 
paraparesis 
Raised ICP/ 
Cerebral Edema 
N/A 
N/A 
Focal/local edema on 
neuroimaging e 
Diffuse cerebral edema on 
neuroimaging; Decerebrate 
or Decorticate posturing; or 
Cranial nerve VI palsy; or 
Papilledema; or Cushing's 
triad 
ASTCT, American Society for Transplantation and Cellular Therapy; CTCAE, Common Terminology Criteria for Adverse Events; 
ICANS, immune effector cell-associated neurotoxicity syndrome; ICE, immune effector cell-associated encephalopathy; ICP, 
intracranial pressure; EEG, electroencephalogram; N/A, not applicable. 
a 
ICANS grade is determined by the most severe event (ICE score, level of consciousness, seizure, motor findings, raised 
ICP/cerebral edema) not attributable to any other cause. For example, a subject with an ICE score of 3 who has a generalized 
seizure is classified as having Grade 3 ICANS. 
b 
A subject with an ICE score of 0 may be classified as having Grade 3 ICANS if the subject is awake with global aphasia. But a 
subject with an ICE score of 0 may be classified as having Grade 4 ICANS if the subject is unarousable. 
c 
Depressed level of consciousness should be attributable to no other cause (e.g. no sedating medication). 
d 
Tremors and myoclonus associated with immune effector cell therapies may be graded according to CTCAE v5.0 but they do 
not influence ICANS grading. 
e 
Intracranial hemorrhage with or without associated edema is not considered a neurotoxicity feature and is excluded from ICANS 
grading. It may be graded according to CTCAE v5.0. 
Reference: Lee 2019. 
 
Refer to Appendix IV for Management Guidelines. 
8.9 Vascular Leak Syndrome 
Neither administration of allogeneic NK cells nor autologous IL-2 activated NK 
infusions have been associated with vascular leak syndrome in our previous 
experience. Nevertheless, patients are monitored for weight gain and pulmonary 
edema during the dose limiting toxicity assessment period (through Day 28) and 
the retreatment period if applicable. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 44 of 79 
CPRC #2020LS001 
 
8.10 Enoblituzumab Adverse Events 
The following were the most common side effects that were considered related to 
single-agent enoblituzumab administration and were seen in at least 1 of 10 adult 
participants. As of 13 April 2019, these side effects have been generally mild or 
moderate. 
  
Very Common (≥10%) 
• Infusion related reactions (IRRs) including CRS – Refer to Section 8.1 
• Tiredness 
• Nausea 
• Chills 
• Vomiting 
A total of 11 patients have experienced serious side effects that were considered 
related to enoblituzumab. A serious side effect that occurred in 3 or more patients 
was infusion related reactions. 
 
9 
Clinical Evaluations and Procedures  
Day 1 is equal to the day the 1st dose of FT516 is given. Day 1 is the anchor day for 
the study calendar. Although a cell infusion with lymphodepleting chemotherapy, there 
is no Day 0 in this calendar.  
 
For Patient Cohorts 4 and 5 only: The 1st dose of enoblituzumab is given 1 to 2 days 
before the start of the cyclophosphamide/fludarabine. Subsequent doses are given 
every 3 weeks (±2 days) from the targeted dosing day. 
 
A minimum of 48 hours must separate the last dose of fludarabine and the 1st dose of 
FT516. The 1st dose of FT516 may be delayed for up to 7 days after the last dose of 
fludarabine in the event FT516 cannot be given as planned. The 1st dose of FT516 
equals Day 1. 
 
A window of ±1 day for scheduling issues is permitted for Day 1, Day 8, and Day 15.  
 
As detailed in Section 7.4, if on the day of the planned treatment, the study investigator 
feels it is not in the best interest to treat the patient, the FT516/IL-2 may be: 
 Delayed for up to 48 hours adjusting future time points to maintain timing OR 
 Skipped and the patient scheduled for the next planned visit. Skipped dose(s) are 
not made up. 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 45 of 79 
CPRC #2020LS001 
 
Scheduled evaluations up to Day 29 (end of DLT period) may be performed ±1 days 
from the targeted date; assessments to be performed after Day 29 may be done ±3 
days of the targeted date. In addition, targeted days may be altered as clinically 
appropriate. 
 
Disease assessments are done per standard of care and for the purposes of follow-
up disease and survival status the disease assessment closest to the targeted follow-
up date should be used for month 3, 6, 9, and 12 follow-up time point. Note: these 
same time points apply to patients who are continuing enoblituzumab as disease 
status and survival are secondary endpoints.  

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 46 of 79 
CPRC #2020LS001 
 
9.1 Required Clinical Care Evaluations   
 
Screening1
Within 28 days 
of registration 
Prior to 1st 
dose of 
study drug  
Enoblituzumab 
(Day -6) 
Level 4 and 
Level 5 only 
CY/FLU  
Day 
1 
Day 
3 
Day 
8 
Day 
15 
Day 
22 
Day 29 
(end of 
DLT 
period) 
Day 
36 
Day 43 and 
every 3 weeks 
for patients 
continuing on 
enoblituzumab 
Dz 
assess 
every 3 
months 
from 
Day 36 5 
3, 6, 9 
and 12 
months 
from 
Day 1 
End of 
Treat-
ment 
Visit10 
#1 
(Day 
-5) 
#2 
(Day 
-4) 
Consent 
X1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening Assessment 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical History 
X 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
Physical Exam 
X 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
 
X 
Provider Assessment 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
 
 
 
Weight 
 
 
X 
X 
 
X8 
X8 
X8 
X8 
X8 
X8 
X8 
X 
 
 
X 
Height 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vitals and Pulse Oximetry 
X 
 
X 
 
 
X6 
 
X6 
X6 
X 
X 
 
X 
 
 
 
GOG Performance Status 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
ICANS (neurotoxicity) 
monitoring)7 
X 
 
X 
 
 
X7 
X 
X7 
X7 
X 
X 
X 
 
 
 
 
Toxicity Assessment (refer to 
Section 10.2 for AE 
documentation requirements) 
X 
 
X 
 
 
X 
X 
X 
X 
X 
X 
 
 
 
 
 
Survival Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Disease Response Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X5 
 
CBC, diff, plt 
X 
 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
Basic metabolic panel (BMP)3 
 
 
 
 
 
X 
X 
 
 
 
 
 
 
 
 
 
Comprehensive metabolic panel 
(CMP) or equivalent4 
X 
 
X 
X 
 
 
 
X 
X 
X 
X 
X 
X 
 
 
X 
CRP. Ferritin, IL-6  
 
 
 
 
 
Only if symptoms or diagnosis of CRS (refer to Section 
8.6) 
 
 
 
 
CA-125 
X 
 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
 
Urine or serum pregnancy test 11 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eGFR 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disease staging by iRECIST 
X 
 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
 
CT or PET-CT of chest, 
abdomen and pelvis 
X1 
 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
 
Brain CT or MRI 
X2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PFTs 
X2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EKG 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Echocardiogram or MUGA or 
cardiac MRI 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IP catheter placement  
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enoblituzumab IV (COHORT 4 
and LEVEL 5 Only) 
 
 
R 
 
 
 
 
 
 
R 
 
 
R (continue every 3 weeks until PD) 
 
FT516/IL-2 IP 
 
 
 
 
 
R 
 
R 
R 
 
 
 
Re-treat9 
 
 
 
R= Research – do not charge to insurance  

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 47 of 79 
CPRC #2020LS001 
 
1 within 14 days for labs required for eligibility - For screening, prior disease assessments may be used if they were performed within 42 days of the 1st FT516 infusion in the 
absence of intervening anti-cancer therapy. Consent is exempt from 28 day limit - may be performed at any time prior to starting study related activity  
2 perform only if known history or as medically indicated 
3 basic metabolic panel consists of BUN, creatinine, calcium, glucose, lytes (CO2, Cl, Na, K)  
4 comprehensive metabolic panel consists of albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), 
calcium, creatinine, glucose, electrolytes (CO2, Cl, Na,, K), total bilirubin, and total protein 
5 Disease restaging every 3 months until disease progression or start of a new treatment then follow for survival only for 12 months from the 1st FT516. For any patient receiving 
FT516 Follow-up transferred to the LTFU protocol CPRC #2020LS072 
6 Vital signs include oral temperature, systolic and diastolic blood pressure, heart rate, respiration rate, and pulse oximetry. On days of FT516 administration, collect as follows: 
within 15 minutes prior to infusion of FT516, at 10 (±5) minutes during infusion, and every 15 (±5) minutes for 1 hour following the end of infusion of the last administered bag of 
FT516. On days of enoblituzumab collect as follows: within 15 minutes of starting the enoblituzumab, every 15 minutes (± 5 minutes for the first hour of the infusion, every 30 
minutes (±5 minutes) thereafter until infusion end, upon discontinuing infusion, and before the patient is discharged from the clinic 
7 Neurotoxicity will be monitored using the ASTCT guidelines for grading ICANS based on the criteria in Section 8.8. ICANS monitoring will occur just prior to start of lympho-
conditioning, at specified time points, and as needed in to document complete resolution to baseline status. On FT516 dosing days, assessment for ICANS should be done 
prior to infusion, 2 to 4 hours after FT516 administration and at time of discharge the post-infusion extends beyond 4 hours. Unscheduled assessments should be 
performed if new or worsening ICANS is suspected. In cases of documented changes in the ICANS grading, follow-up assessments should be performed until resolution to 
baseline or patient discontinuation from the study, whichever occurs earlier. Refer to Section 8.8 for details.  
8 To monitor for vascular leak syndrome per Section 8.9 
9 Re-treatment may be an option for patients with stable disease or better based on the Day 36 reassessment. Refer to Section 6.3 and Section 7.8 for additional information.  
10 
End of Treatment visit approximately 30 days (± 8 days) after the last dose of enoblituzumab (or FT516) whichever is later   
11 
Woman of childbearing potential and still have the anatomy (uterus and ovaries) to get pregnant must have a negative pregnancy test (urine or serum) within 14 days of 
study enrollment 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 48 of 79 
CPRC #2020LS001 
 
9.2 Patient Research Related Evaluations 
 
Baseline (Prior 
to 1st dose of 
study drug) 
Prior to 
enoblituzumab 
(Day -6) 
COHORT 4 
and  5 ONLY 
Prior to 
LD 
chemo 
Day 
1 
Day 
3 
Day 
8 
Day 
15 
Day 
22 
Day 
29 
Day 
36 
Day 43 
Research Sample Drawing Coincides with 
a SOC visit closest to the targeted time 
point 
3 
months 
from 
Day 1 
6 
months 
from 
Day 1 
9 
months 
from 
Day 1 
12 
months 
from Day 
1 
Enoblituzumab 
 
X 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
FT516 treatment 
 
 
 
X 
 
X 
X 
 
 
 
 
 
 
 
 
ferritin, CRP (to FV lab per SOC) 1 
X 
 
 
X 
 
 
 
 
X 
 
 
 
 
 
 
Six 10 ml green top tubes – collect prior to 
the day’s treatment (if applicable) 5 
X5 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X (30 
ml) 
X (30 
ml)  
X (30 
ml) 
X (30 
ml) 
One 10 ml of red top tube – collect prior to 
the day’s treatment (if applicable) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
PRA anti-HLA antibodies 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
IP fluid (ascites preferred over washings) – 
collect prior to the day’s treatment (if 
applicable) Refer to Section 9.2.1 
At time of IP 
catheter 
placement 
 
 
X 
 
X 
X 
X 
X2 
X3 
If 
retreat 
 
 
 
 
Tumor biopsy by IR (if feasible)  6 cores (5-
10 mm) preferred but less is acceptable – to 
BioNet 
At time of IP 
catheter 
placement 
 
 
 
 
 
 
 
 
X3 
 
 
 
 
 
Safety baseline:  
1 x 3 ml red top serum tube  
1 x 10 ml green top tube 
– store frozen and batch ship to Fate 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Safety follow-up:  
1 x 3 ml red top serum tube  
1 x 10 ml green top tube 
1 x 6 ml yellow top tube 
 – store frozen and batch ship to Fate 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
(not 
collected at
9 months) 
X 
1 – Baseline ferritin and CRP are paid for by the study – if CRS occurs, additional ferritin and CRP levels are done as part of clinical care per Section 9.1 as detailed in 1st paragraph 
below this table 
2- if NK cells are not present at Day 22, do not collect ascites or IP washing at Day 29 
3 - at time of IP catheter removal (Day 36 if no re-treatment or at time of IP catheter removal if re-treatment) 
4- Collect 5ml ascites-aliquot in 5 tubes minimum-200ul/vial, rest as 1ml/vial. Stored frozen for batching shipping to FATE for NK cell PKs  
5 - At TTL: PBMCs are isolated from the heparin/green tube at pre-designated time points for PCR testing by Fate 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 49 of 79 
CPRC #2020LS001 
 
Note: if a patient is not abiding by the required clinical care calendar (Section 9.1), the 
collection schedule of research related samples may be altered or discontinued on an 
individual patient basis, as appropriate. During follow-up no visit will be solely for 
research and instead be linked with a standard of care visit closest to the targeted 
research related timepoint.  
 
All research samples go to the Masonic Cancer Center’s Translational Therapy Lab 
(TTL) unless otherwise indicated. Baseline and Day 29 ferritin and CRP and PRA anti-
HLA antibodies testing are charged to research but run in the treatment center’s 
clinical lab. If additional ferritin and/or CRP levels are collected as part of good medical 
care (i.e. development of signs of CRS) they are to be charged as standard of care. 
 
For all patients receiving FT516, samples as designated in the above table are 
shipped from TTL to Fate. For Cohorts 4 and 5 only, serum and ascites/IP wash 
samples are provided to MacroGenics by TTL to determine enoblituzumab levels.  
 
It is recognized that with novel therapies as used in this study, the timing of protocol 
directed research samples may miss important patient specific events. For this 
reason, blood and/or IP fluid may be collected at up to 3 additional time points that are 
not specified above.  
 
Samples to evaluate lymphocyte number and phenotype will be collected as detailed 
above for the Masonic Cancer Center Translational Therapy Lab (TTL) along with 
serum (red top tubes) for measure of cytokines that can reflect immune activation.  
 
Flow cytometry analysis of a fraction of the PBMC will detect surface markers that 
define lymphocyte subsets (NK, NKT, B, and T cells, both CD4 and CD8), as well as 
intracellular markers that define regulatory T cells (Foxp3) and proliferating cells 
(Ki67). All remaining PBMC will be cryopreserved in 10% DMSO and stored in liquid 
nitrogen for future testing, if subject agreed to future storage at the time of initial 
consent. 
 
Samples may be sent to laboratories outside of the University of Minnesota in cases 
where testing is not available internally as embedded in the patient consent form. 
9.2.1 Intraperitoneal (IP) Fluid Collection 
Ascites is preferred and a collection of such should be attempted first. It is 
recommended to obtain a minimum of 200cc and up to 500cc if ascites is present. 
Lower or higher volumes are acceptable. Any ascites collected, regardless of the 
volume, will be submitted to TTL as a separate sample from peritoneal washings if 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 50 of 79 
CPRC #2020LS001 
 
both obtained. The higher the volume of ascites submitted, the better the yield of 
Tumor Ascites Lymphocytes (TALs).  
 
If ascites is drained for clinical care at other times during this timeframe, a sample (up 
to 500 cc) may be submitted to TTL as an additional time point.  
 
If no ascites is present or less than 50cc is collected, peritoneal washings will be 
performed. A volume of 250cc of room temperature NS will be infused into the 
abdomen. After infusion the patient will be asked to change position (right lateral, left 
lateral, Trendelenburg (feet higher than head by 30 degrees), reverse Trendelenburg) 
at 5-minute intervals to ensure adequate intra-abdominal distribution. Fifty (50) cc of 
infusate will then be retrieved through the indwelling catheter. 
 
If a minimum of 50cc of infusate is not retrieved, another 250 cc of NS will be infused 
and the above process repeated. If after this 50cc of infusate have not been retrieved, 
the process will be terminated, however, any amount of infusate that is retrieved 
should be sent to TTL for testing. 
9.2.2 Tumor Biopsies  
Tumor biopsies will be performed if feasible. The inability or failure to do a biopsy will 
not be considered a protocol deviation. It is preferred that 6 cores (5-10 mm) be 
collected. It is understandable that it may not always be possible to obtain 6 cores and 
in such cases testing will be prioritized based on the number of cores received. The 
inability to collect any tumor samples or an insufficient amount will not be considered 
a protocol deviation. 
 
Samples go to BioNet.  
 
10 Event Monitoring, Documentation, and Reporting 
For the purpose of the study FT516 and IL-2 are considered the investigational 
products for all patients. In addition, enoblituzumab is an investigational agent for 
patients treated in Cohort 4 or Cohort 5. 
 
Adverse Reactions will be reported to the FDA per 21 CFR 312.32. 
 
Toxicity and adverse events will be classified and graded according to NCI's Common 
Terminology Criteria for Adverse Events V 5.0 (CTCAE) and reported on the schedule 
below. A copy of the CTCAE can be downloaded from the CTEP home page.  

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 51 of 79 
CPRC #2020LS001 
 
(https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v
5_Quick_Reference_5x7.pdf) 
 
An exception to the use of CTCAE will be for the assessment of cytokine release 
syndrome (CRS). Individual adverse events which are associated with CRS will be 
graded per CTCAE; however the ultimate assessment will be made using a revised 
grading system for CRS as presented by Lee et al (2019).  
Table 4: ASTCT Cytokine Release Syndrome Consensus Grading System a 
CRS Parameter 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Fever b 
Temperature ≥38˚C 
Temperature ≥38˚C 
Temperature ≥38˚C 
Temperature ≥38˚C 
With either: 
Hypotension 
None 
Not requiring 
vasopressors 
Requiring 
vasopressors 
with/with-out 
vasopressin 
Requiring multiple 
vasopressors 
(excluding 
vasopressin) 
And/or c 
Hypoxia 
None 
Requiring low-flow 
nasal cannula d or 
blow-by 
Requiring high-flow 
nasal cannula, 
facemask, 
non-rebreather mask, 
or venturi mask 
Requiring positive 
pressure 
(e.g., CPAP, 
BiPAP, intubation 
and mechanical 
ventilation) 
ASTCT, American Society for Transplantation and Cellular Therapy; BiPAP, bilevel positive airway pressure; 
CPAP, continuous positive airway pressure; CRS, cytokine release syndrome; NCI CTCAE, National Cancer 
Institute Common Terminology Criteria for Adverse Events. 
a 
Organ toxicities associated with CRS may be graded according to NCI CTCAE v5.0, but they do not influence 
CRS grading. 
b 
Fever is defined as temperature ≥38°C not attributable to any other cause. In subjects who have CRS then 
receive antipyretics or anti-cytokine therapy such as tocilizumab or steroids, fever is no longer required to grade 
subsequent CRS severity. In this case, CRS grading is driven by hypotension and/or hypoxia. 
c 
CRS grade is determined by the more severe event: hypotension or hypoxia not attributable to any other cause. 
For example, a subject with temperature of 39.5°C, hypotension requiring one vasopressor and hypoxia 
requiring low flow nasal cannula is classified as having Grade 3 CRS. 
d 
Low-flow nasal cannula is defined as oxygen delivered at >6 liters/minute. Low flow also includes blow-by 
oxygen delivery, sometimes used in pediatrics. High-flow nasal cannula is defined as oxygen delivered at 
>6 liters/minute. 
Source: Lee et al. 2019. 
The following definitions of adverse events (AEs) and serious adverse events (SAEs) 
will determine whether the event requires expedited reporting via the SAE Report 
Form in addition to routine documentation in the OnCore AE case report form (CRF).  
10.1 Event Terminology 
Adverse Event:  Any untoward medical occurrence associated with the use of a 
drug in humans, whether or not considered drug related. 
 
Suspected Adverse Reaction: Any adverse event for which there is a reasonable 
possibility that the drug caused the adverse event. For the purposes of IND safety 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 52 of 79 
CPRC #2020LS001 
 
reporting, ‘reasonable possibility’ means there is evidence to suggest a causal 
relationship between the drug and the adverse event. A suspected adverse 
reaction implies a lesser degree of certainty about causality than adverse reaction, 
which means any adverse event caused by a drug. 
 
Adverse Reaction: Any adverse event caused by a drug. Adverse reactions are a 
subset of all suspected adverse reactions where there is reason to conclude that 
the drug caused the event. 
  
Serious Adverse Event:  An adverse event is considered “serious” if, in the view of 
either the investigator or IND Sponsor, it results in any of the following outcomes:  
 Death 
 A life-threatening adverse event 
 Inpatient hospitalization or prolongation of existing hospitalization 
 A persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
 A congenital anomaly/birth defect 
 
Important medical events that may not result in death, be life-threatening, or 
require hospitalization may be considered serious when, based upon appropriate 
medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this 
definition.  
 
Unexpected Event: An adverse event or suspected adverse reaction is considered 
“unexpected” if it is not listed in the protocol-related documents (e.g. protocol, 
consent documents, investigator brochure) or is not listed at the specificity or 
severity that has been observed or given the characteristics of the subject 
population being studied.  
 
The following definitions are from the Masonic Cancer Center’s Standard 
Operating Procedure (SOP) Deviation Reporting: 
 
Major Deviation: A deviation or violation that impacts the risks and benefits of the 
research; may impact subject safety, affect the integrity of research data and/or 
affect a subject’s willingness to participate in the research. Deviations that place a 
subject at risk, but do not result in harm are considered to be major deviations. 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 53 of 79 
CPRC #2020LS001 
 
Minor Deviation: A deviation or violation that does not impact subject safety, 
compromise the integrity of research data and/or affect a subject’s willingness to 
participate in the research. 
10.2 Event Monitoring and Documentation Requirements 
Monitoring for adverse events will begin with the insertion of the IP catheter 
through the removal of the IP catheter through the end of the dose limiting toxicity 
period (28 days after the 1st dose of FT516). Note: if a patient is not abiding by the 
planned treatment schedule, the documentation of adverse events may be altered 
or discontinued on an individual patient basis, as appropriate. During follow-up no 
visit will be solely for research and instead be linked with a standard of care visit 
closest to the targeted research related timepoint. 
 
For patients receiving enoblituzumab maintenance (Cohort 4 and 5 only), AE 
monitoring continues through 28 days after the last dose or enoblituzumab. 
 
The toxicity associated with the cyclophosphamide and fludarabine (CY/FLU) 
preparative regimen is well known and will not be documented unless the event 
meets the definition of a serious adverse event. Potential risks of CY/FLU are 
detailed in Appendix III.  
 
Therefore, adverse event documentation for the purposes of this study will focus 
on  
 Adverse events of special interest requiring targeted monitoring including 
infusion related reactions (IRR), neurotoxicity, vascular leak syndrome, and 
cytokine release syndrome as summarized in Table 5. Refer to Section 9.1 
for timing/details. 
 Any event within 28 days of the 1st FT516 infusion meeting the definition of 
dose limiting toxicity or for Step 1, an unacceptable toxicity per Section 10.3.  
 Any event meeting the definition of a serious adverse event, regardless of 
attribution  
 All Grade 3 and 4 adverse events regardless of attribution 
 Grade 2 adverse events felt possibly, probably or related to either 
enoblituzumab or FT516 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 54 of 79 
CPRC #2020LS001 
 
 
Table 5: Adverse Events of Special Interest Enoblituzumab and FT516/IL-2 
AE of Special 
Interest 
Monitoring summary  
Infusion related 
reaction to 
enoblituzumab 
Refer to Section 7.2 for management of IRR - On days of enoblituzumab 
collect as follows: within 15 minutes of starting the enoblituzumab, every 
15 minutes (± 5 minutes for the first hour of the infusion, every 30 minutes 
(±5 minutes) thereafter until infusion end, upon discontinuing infusion, 
and before the patient is discharged from the clinic 
Infusion related 
reaction to FT516  
Refer to Section 8.2 - Vital signs include oral temperature, systolic and 
diastolic blood pressure, heart rate, respiratory, and pulse oximetry. On 
days of FT516 administration, collect as follows: within 15 minutes prior to 
the infusion of FT516, at 10 (±5) minutes during infusion, and every 15 
(±5) minutes for 1 hour following the end of infusion of the last 
administered bag of FT516 
Cytokine Release 
Syndrome or CRS-
Like Symptoms 
Grade per Lee 2019 in Section 10 
In the event of CRS obtain CRP and ferritin levels per Section 9.1 
Neurotoxicity 
Neurotoxicity will be monitored using the ASTCT guidelines for grading 
ICANS based on the criteria in Section 8.8. ICANS monitoring will occur 
just prior to start of lympho-conditioning, at specified time points, and as 
needed in to document complete resolution to baseline status. On FT516 
dosing days, assessment for ICANS should be done prior to 
infusion, 2 to 4 hours after FT516 administration and at time of 
discharge the post-infusion extends beyond 4 hours. Unscheduled 
assessments should be performed if new or worsening ICANS is 
suspected. In cases of documented changes in the ICANS grading, 
follow-up assessments should be performed until resolution to baseline or 
patient discontinuation from the study, whichever occurs earlier.   
Vascular Leak 
Syndrome 
Potential risk of IL-2 – assessed by weight measures and signs of 
pulmonary edema  
10.3 Dose Limiting Toxicity Event/Stopping Rule Documentation and 
Reporting 
The following events require special documentation and reporting in addition to 
recording as an adverse event and reporting as a serious adverse event if that 
criteria is met. 
10.3.1 During Fast-Track Enrollment Only 
During Stage 1, Step 1 of fast-track enrollment only (cohorts of 1 patient), the 1st 
patient experiencing any one of the following adverse events within 28 days of the 
1st FT516 dose triggers a change to 3 patients per cohort (Stage 1, Step 2). These 
definitions of unacceptable adverse events only are used for assessment in single 
patient cohorts.  
 Abdominal pain that is unresponsive to management lasting more than 48 hours 
not attributable to disease status 
 Grade 3 infusion related reaction (per CTCAE V5) 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 55 of 79 
CPRC #2020LS001 
 
If a patent experiences a dose limiting toxicity (defined in next section), enrollment 
moves directly to Stage 2 (CRM). 
10.3.2 Dose Limiting Toxicity (All Patients) 
All patients are monitored for dose limiting toxicity (DLT). DLT is defined as any 
treatment emergent toxicity at least possibly related to the study treatment meeting 
one of the following criteria based on CTCAE v5 within 28 days (14 days for 
ascites) of the 1st FT516 infusion (for Cohort 4 and 5, DLT assessment starts with 
enoblituzumab and continues for 28 days after 1st FT516): 
 Grade 3 organ toxicity (pulmonary, hepatic, renal, or neurologic) not pre-existing 
and lasting more than 72 hours  
 Any non-hematologic Grade 4 or 5 toxicity 
 Neutrophil count decreased ≥ Grade 4 that persists at Day 28 despite use of 
growth factor support 
 Grade 3 or greater abdominal pain lasting more than 4 consecutive days and 
not controlled by standard analgesics 
 Grade 3 or greater ascites within 14 days after FT516 administration in patients 
who had no ascites or Grade 1 ascites at enrollment and is not attributable to 
disease progression 
 
In addition to documenting the event in the study’s CRF’s, all DLT are to be 
documented on the Event Form found in OnCore per Masonic Cancer Center 
procedures. 
10.3.3 Early Stopping Rule Events (All Patients) 
Stopping rules are in place during this study to stop the trial in case there is 
excessive toxicity. The following events must be reported within 24 hours of 
knowledge using the Stopping Rule form. 
o Stopping Rule for Excessive DLT 
o Infusion Related Reaction within 28 days of the 1st dose of FT516 (34 days 
after the 1st dose of enoblituzumab in Cohorts 4 and 5) 
o Early Death (Grade 5 Event) within 28 days after the last dose of FT516 (21 
days after Dose 2 of enoblituzumab in Cohorts 4 and 5) and not attributable 
to disease progression. 
Any one death, suspends study enrollment per Section 13.4. 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 56 of 79 
CPRC #2020LS001 
 
10.4 SAE and Death Documentation  
Any event meeting the definition of a serious adverse event (SAE) requires 
documentation using the MCC SAE Report Form in OnCore.  
 
Deaths, including due to disease within 1 year after the FT516 cell infusion will be 
recorded as an SAE. Deaths due to disease should be recorded as a Grade 5 
“Neoplasms benign, malignant and unspecified (including cysts and polyps) – 
Other (Progressive Disease).  
 
In addition, the death date and cause must be reported in the patient follow-up tab 
in OnCore using the comment field in the survival status section to record the 
cause.  
10.5 Expedited Reporting Requirements 
The following events require expedited reported: 
 
Report to: 
Criteria for reporting: 
Timeframe: 
Form to Use: 
Submission 
email address 
Advarra  
unanticipated problems involving risks to subjects 
or others; unanticipated adverse device 
effects; protocol violations that may affect the 
subjects’ rights, safety, or well-being and/or the 
completeness, accuracy and reliability of the study 
data; subject death; suspension of enrollment; or 
termination of the study  
promptly and 
no later than 
2 weeks (10 
business 
days) from 
the time the 
investigator 
learns of the 
event 
Refer to the 
Advarra IRB 
Handbook 
Advarra via study 
specific CIRBI Link 
UMN IRB 
Refer to Submitting Updates in ETHOS – External IRB Study/Site 
FDA 
 
Unexpected and fatal or unexpected and life 
threatening suspected adverse reaction 
no later than 
7 Calendar 
Days 
MCC SAE Report 
Form 
Submit to FDA as 
an amendment to 
IND  
with a copy to Fate 
Therapeutics at 
safety@fatetherap
eutics.com, if 
Cohort 4 or 5 to 
MacroGenics 
saereports@Macr
oGenics.com   
1) Serious and unexpected suspected adverse 
reaction or 
2)  increased occurrence of serious suspected 
adverse reactions over that listed in the protocol or 
investigator 
brochure or 
3) findings from other sources (other studies, 
animal or in vitro testing) 
no later than 
15 Calendar-
Days 
All other events per CFR 312.33  
at time of 
annual 
report 
IND annual report 
MacroGenics, 
Inc 
For patients assigned to enoblituzumab: all SAEs, 
regardless of causality or expectedness 
(pregnancy N/A in this study) 
within 7 
calendar 
days of 
awareness 
MCC SAE Report 
Form  
saereports@Macr
oGenics.com 
Fate 
Therapeutics 
All SAEs  
no later than 
5 Calendar 
Days 
MCC SAE Report 
Form  
Fate Therapeutics 
at 
safety@fatetherape
utics.com 
Suspected Unexpected Serious Adverse Reaction 
(SUSAR) 
No later than 
3 Calendar 
Days 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 57 of 79 
CPRC #2020LS001 
 
The Masonic Cancer Center (MCC) SAE Coordinator receives an OnCore generated 
notification for any SAE, DLT, or stopping rule event. The MCC SAE Coordinator or 
designee is responsible for reviewing each report and determines if the event is reported 
in real time to the MCC Data and Safety Monitoring Council in real time or as part of 
quarterly summary report required for any high risk trial.  
 
11 Investigational Products Information 
11.1 Enoblituzumab 
Enoblituzumab will be administered at a dose of 15 mg/kg, initially calculated 
based on the patient’s actual weight prior to the 1st dose (baseline) measurement. 
Significant (≥ 10%) change in body weight from baseline should prompt 
recalculation of the dose. Refer to the Pharmacy Manual for further instructions on 
allowable parameters for dose rounding of enoblituzumab. 
11.1.1 Availability 
For the purposes of this study, enoblituzumab will be provided by 
MacroGenics. 
11.1.2 Storage 
Enoblituzumab will be stored in the University of Minnesota Investigational 
Drug Services (IDS) Pharmacy. 
11.1.3 Preparation 
The desired amount of enoblituzumab should be withdrawn from the vial(s) 
and diluted to the appropriate final concentration with 0.9% Sodium Chloride 
Injection USP (normal saline), according to the instructions provided in the 
Pharmacy 
Manual. 
A 
sterile, 
non-pyrogenic, 
low-protein 
binding 
polyethersulfone (PES) 0.2 micron in-line filter administration set must be 
used for IV administration of enoblituzumab. The infusion bag containing 
enoblituzumab should be gently inverted to mix the solution. The dose 
solution should be administered via IV infusion over 120 (± 15) minutes with 
a commercially available infusion pump.” 
11.1.4 Potential Toxicities 
Refer to Section 8 for potential toxicities. 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 58 of 79 
CPRC #2020LS001 
 
11.2 FT516 
FT516 is an investigational product and can only be used and administered under 
an FDA approved protocol. For the purposes of this study FT516 is provided by 
Fate Therapeutics.  
 
FT516 will be provided as a cryopreserved bag, thawed at the site of administration 
and administered by gravity without an in-line filter intraperitoneally via 
intraperitoneal catheter.  
 
Refer to Section 8 for potential toxicities. 
11.3 Interleukin-2 
IL-2 is not approved for the indication and method of administration used in this 
study, although it has previously been given at the same dose intraperitoneally in 
previous studies performed at the University of Minnesota under IND 17568 (S/I 
Melissa A. Geller, MD). Dr. Geller provided a letter of authorization to in its review 
as part of the initial IND application for this study.  
 
For the purposes of this study, IL-2 will be purchased by the University of 
Minnesota Fairview Investigational Drug Services (IDS) pharmacy. The IL-2 
infusion will be prepared in IDS. 
12 Study Data Collection and Monitoring 
12.1 Data Management 
This study will collect regulatory and clinical data using University of Minnesota 
CTSI’s instance of OnCore® (Online Enterprise Research Management 
Environment). The Oncore database resides on dedicated secure and PHI 
compliant servers. The production server is located in the UMN datacenter 
(WBOB).  
 
Additional immune monitoring data about correlative laboratory samples 
generated by the Masonic Cancer Center Translational Therapy Laboratory (TTL) 
from the protocol-directed correlative research samples is stored in their 
Laboratory Information Management System (LIMS).The LIMS database 
application is also stored on a production server located in the UMN datacenter 
(WBOB) and is managed by the Academic Health Center 
 
Key study personnel are trained on the use of OnCore and will comply with protocol 
specific instructions embedded within the OnCore. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 59 of 79 
CPRC #2020LS001 
 
12.2 Case Report Forms 
Participant data will be collected using protocol specific electronic case report 
forms (e-CRF) developed within OnCore based on its library of standardized forms. 
The e-CRF will be approved by the study’s Principal Investigator and the 
Biostatistician prior to release for use. The Primary Clinical Research Coordinator 
or designee will be responsible for registering the patient into OnCore at time of 
study entry, completing e-CRF based on the patient specific calendar, and 
updating the patient record until patient death or end of required study 
participation.  
12.3 Data and Safety Monitoring Plan (DSMP) 
The Data and Safety Monitoring Plan of this study will be in compliance with the 
University of Minnesota Masonic Cancer Center's Data & Safety Monitoring Plan 
(DSMP), which can be accessed at http://z.umn.edu/dsmp. 
 
For the purposes of data and safety monitoring, this study is classified as high risk 
(under a locally held IND). Therefore the following requirements will be fulfilled: 
 At least quarterly review of the study’s progress by the Masonic Cancer Center 
Data and Safety Monitoring Council (DSMC). 
 At least twice yearly monitoring of the project by the Masonic Cancer Center 
monitoring services. 
 The PI will oversee the submission of all reportable adverse events per 
Section 10.5 to the Advarra, the FDA, Fate Therapeutics, and MacroGenics. 
 
IND Annual Reports 
In accordance with regulation 21 CFR § 312.33, the IND Sponsor (Dr. Geller) will 
submit a progress report annually. The report will be submitted within 60 days of 
the anniversary date that the IND went into effect.  
12.4 Study Monitoring 
The investigator will permit study-related monitoring, audits, and inspections by the 
study’s Principal Investigator and/or any designees, the IRB of record, government 
regulatory bodies, and University of Minnesota compliance groups. The 
investigator will make available all study related documents (e.g. source 
documents, regulatory documents, data collection instruments, study data, etc.). 
The investigator will ensure the capability for inspections of applicable study-
related facilities (e.g. pharmacy, diagnostic laboratory, etc.) will be available for 
trial related monitoring, audits, or regulatory inspections. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 60 of 79 
CPRC #2020LS001 
 
12.5 Record Retention 
Study records including source data, copies of case report forms, consent forms, 
HIPAA authorizations, and all study correspondence will be retained in a secured 
facility until permission is received that the documents are no longer needed.  
 
In addition, the Clinical Trials Office (CTO) will keep a master log in OnCore of all 
patients participating in the study with sufficient information to allow retrieval of the 
medical records for that patient.  
 
Please contact the CTO before destroying any study related records. 
13 Statistical Considerations  
13.1 Study Design, Objectives and Endpoints  
This Phase I study will test up to 5 dose strategies of FT516 to determine the 
maximum tolerated dose (MTD) of FT516 with a maximum enrollment of 31 
patients.  
 
There are 5 potential levels defined for this study. The trial will be conducted with 
no intra-patient escalation. The starting dose will be dose 9x107 FT516 cells/dose 
with no enoblituzumab. The subsequent planned cohorts will be 3x108 FT516 
cells/dose with no enoblituzumab, and then 9x108 FT516 cells/dose with no 
enoblituzumab. Dose escalation will continue in combination with enoblituzumab 
starting at 1 dose below the highest dose reached from the 1st 3 cohorts given that 
we reach at least Cohort 2 without enoblituzumab. This will potentially continue up 
through 9x108 FT516 cells/dose + enoblituzumab. Given that little to no toxicity is 
expected, the MTD will be determined using an adaptation of the continual 
reassessment method (CRM) (O’Quigley, 1996). A cohort of 1 patient will start at 
Cohort 1 with subsequent planned cohorts as described in Table 6: 
 
Table 6. Infuse FT516 cell product at the assigned dose on Day 1, Day 8 and Day 15  
Cohort 
FT516 Dose IP (cells per dose) 
1 
Monotherapy: IP FT516 at 9 x 10^7 cells/dose on Day 1, 8, and 15 
2 
Monotherapy: IP FT516 at 3 x 10^8 cells/dose on Day 1, 8, and 15 
3 
Monotherapy: IP FT516 at 9 x 10^8 cells/dose on Day 1, 8, and 15 
4 
Safe FT516 dose (MTD-1) from 1st 3 levels + IV enoblituzumab on Day -6 
5 
Highest FT516 dose (MTD) from 1st 3 levels + IV enoblituzumab on Day -6 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 61 of 79 
CPRC #2020LS001 
 
The Phase I trial will be conducted in two consecutive stages: Stage 1 Step 1 will 
enroll one patient at consecutively increasing doses until any of the following 
adverse events occurs within 28 days of the 1st dose of FT516:  
 Abdominal pain that is unresponsive to management lasting more than 48 
hours not attributable to disease status 
 Grade 3 infusion reaction (per CTCAE V5) 
 
At this point Stage 1, Step 2 is initiated and the cohort size will increase from 1 to 
3 patients. Note: if a DLT occurs during Fast-track (Step 1), enrollment moves 
directly to Stage 2 and Step 2 is not used.  
 
At the 1st dose-limiting toxicity (DLT, defined in Section 7.5) occurs, Stage 2 of the 
Phase I trial will be initiated. In this stage, the dose escalation will be based on a 
simple application of the likelihood version of the CRM. A one-parameter model 
has been chosen to link the risk of a DLT to the dose, where the probability of 
toxicity at dose i is modeled as piexp(α) where pi is a constant and α is the 
parameter to be estimated. The goal will be to identify one of the 5 dose level 
strategies corresponding to the desired maximum toxicity rate of ≤25%.  
 
Given that we will have prior data once the CRM is initiated, no “skeleton” 
estimates are needed. If the CRM is initiated, the CRM will continually update the 
toxicity at the end of 28 days after the 3rd patient in each cohort. Each new cohort 
of three patients will be sequentially assigned to the most appropriate dose based 
on the updated toxicity probabilities. The MTD will be identified by the minimum of 
the following criteria: (1) the total sample size of 25 is exhausted, (2) 10 
consecutive patients are enrolled at the same dose or (3) the probability that the 
next 5 patients will be allocated to the same dose-level, based on the current 
estimate of the probability of toxicity, exceeds 90%. (Zohar 2001) The function 
‘crm’ from the R package ‘dfcrm’ will calculate posterior means of toxicity 
probabilities. Dose escalation of more than one level is not permitted with this 
design. 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 62 of 79 
CPRC #2020LS001 
 
13.2 Sample Size 
A maximum of 31 patients will be enrolled. Based on the simulations from Table 6 
and Table 7, this should be sufficient and safe to define the MTD.  
 
 
 
 
 
 
 
 
 
 
 
 
Enrollment will most likely include 14 patients, 22 patients if adverse events are 
encountered initially, or it could be as high as 31 patients if DLTs are encountered 
early. Accrual should range from 10-12 patients per year so study accrual is 
expected to be complete within 24-36 months. 
 
Any patient who does not receive at least 1 dose of FT516 will be replaced to 
complete enrollment at a specified dose (e.g. 10 evaluable patients at the MTD).  
13.3 Statistical Analysis  
The primary objective of this trial is to identify the maximum tolerated dose (MTD) 
which will be determined per the study design and consultation with the study 
statistician using R prior to each cohort enrollment. Due to small patient numbers 
at the MTD, estimation of toxicity rates, clinical activity of progression free survival 
(PFS) at 12 months will be estimated in a descriptive format using simple 
frequencies, proportions, means, standard deviations/standard errors, medians 
and ranges and respective plots. Potential censored data such as PFS and 
relapse/progression and NRM may be estimated by Kaplan-Meier curves at 12 
months. Relapse/progression and NRM may be estimated by cumulative 
incidence, treating NRM and relapse as competing risks, respectively. 
 
 
Table 7. Operating characteristics for Adaptive-CRM 
 
Cells/ dose 
Expected DLT 
Excessive DLT 
True 
Probability 
Prob. of 
dose 
N 
True 
Probability 
Probability of 
dose 
N 
9 x 10^7 alone 
1% 
0% 
1 
15% 
32% 
6 
3 x 10^8 alone 
3% 
0% 
1 
30% 
52% 
12 
9 x 10^8 alone 
6% 
0% 
1 
45% 
16% 
6 
Safe dose from 1st 3 
levels(MTD-1) 
+enoblituzumab 
8% 
0% 
1 
60% 
0% 
1 
Highest dose from 1st 
3 levels (MTD) + 
enoblituzumab 
10% 
100% 
10 
70% 
0% 
0 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 63 of 79 
CPRC #2020LS001 
 
13.4 Monitoring Guidelines (Early Study Stopping Rules) 
 
Stopping rules also are in place independent of dose escalation. (Ivanova 2005).  
 
Stopping Rule for Excessive DLT 
A stopping rule is in place during the Phase I study to stop the trial in case there 
are excessive DLTs as defined by updated posterior probabilities throughout the 
trial. At the end of the 28 day evaluation period after each cohort of patients is 
enrolled, new posterior probabilities will be calculated for each dose. The trial will 
be stopped if the posterior probability that the lowest dose is unacceptably toxic 
(> 25% of patients) is greater than 80%. 
  
Infusion Related Reaction within 28 Days of the 1st Dose of FT516 (34 days 
after the 1st dose of enoblituzumab in Cohorts 4 and 5) 
The goal is to construct a boundary based on Grade 3 or greater infusion related 
reaction such that the probability of early stopping is at most 10% if the rate is 
equal to 5% and our sample size is at most 31. With these stipulations, the trial will 
be stopped and reviewed if 2/7, 3/16, 4/28 or 5 patients have events by Day 28. If 
the true probability of infusion related toxicity is 20%, there is an 88% chance of 
triggering the monitoring boundary. 
 
Early Death (Grade 5 Event) within 28 days after the last dose of FT516 (21 
days after Dose 2 of enoblituzumab in Cohorts 4 and 5) 
Enrollment will be suspended and reviewed by the study team with follow-up 
notification to the FDA and IRB of the findings before enrollment is restarted for 
any death within 28 days after the last dose of FT516 (21 days after Dose 2 of 
enoblituzumab in Cohorts 4 and 5) and not attributable to disease progression. 
 
14 Ethical and Regulatory Considerations 
14.1 Good Clinical Practice 
The study will be conducted in accordance with the appropriate regulatory 
requirement(s). Essential clinical documents will be maintained to demonstrate the 
validity of the study and the integrity of the data collected. Master files should be 
established at the beginning of the study, maintained for the duration of the study 
and retained according to the appropriate regulations.  
14.2 Ethical Considerations 
The study will be conducted in accordance with ethical principles founded in the 
Declaration of Helsinki. The IRB will review all appropriate study documentation in 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 64 of 79 
CPRC #2020LS001 
 
order to safeguard the rights, safety and well-being of the patients. The study will 
only be conducted at sites where IRB approval has been obtained. The protocol, 
informed consent, written information given to the patients, safety updates, annual 
progress reports, and any revisions to these documents will be provided to the IRB 
by the investigator.  
14.3 Informed Consent 
All potential study participants will be given a copy of the IRB-approved Consent 
to review. The investigator or designee will explain all aspects of the study in lay 
language and answer all questions regarding the study. If the participant decides 
to participate in the study, she will be asked to sign and date the Consent 
document. Patients who refuse to participate or who withdraw from the study will 
be treated without prejudice. 
15 References  
Actemra® (tocilizumab) injection, for intravenous or subcutaneous use [Prescribing 
Information]. San Francisco, CA. Genentech, Inc.; 2019. 
Arai S, Meagher R, Swearingen M, et al. Infusion of the allogeneic cell line NK-92 in patients 
with advanced renal cell cancer or melanoma: a Phase I trial. Cytotherapy. 2008;10:625-32. 
Bachanova V, Cooley S, Defor TE, et al. Clearance of acute myeloid leukemia by 
haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 
2014;123:38-63. 
Bachanova V, Sarhan D, DeFor TE, et al. Haploidentical natural killer cells induce remissions 
in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer 
Immunol Immunother. 2018;67:483-94. 
Belisle J, Gubbles J, Raphael C, et al. Peritoneal natural killer cells from epithelial ovarian 
cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). 
Immunology. 2007 122, 418–429. 
Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcRIIa-FcRIIIa polymorphisms and 
KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated 
with cetuximab plus irinotecan. J Clin Oncol. 2009;27:1122-9. 
Brudno J, Kochenderfer J. Toxicities of chimeric antigen receptor T cells: recognition and 
management. Blood. 2016;127:3321-30. 
Cancer Stat Facts: Ovarian Cancer https://seer.cancer.gov/statfacts/html/ovary.html 
accessed March 16, 2020. 
Cartron G, DacheuxL, Salles G, et al. Therapeutic activity of humanized anti-CD20 
monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene. Blood. 2002;99:754-
8. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 65 of 79 
CPRC #2020LS001 
 
Cooley S, He F, Bachanova V, et al. First-in-human trial of rhIL-15 and haploidentical natural 
killer cell therapy for advanced acute myeloid leukemia. Blood Advances. 2019;3:1970-80. 
Dahlberg CIM, Sarhan D, Chrobok M, et al. Natural killer cell-based therapies targeting 
cancer: possible strategies to gain and sustain anti-tumor activity. Front Immunol. 2015;6:605. 
Dauplat J, Hacker NF, Nieberg RK, et al. Distant metastases in epithelial ovarian carcinoma. 
Cancer 1987; 60:1561-1566. 
Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in 
patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850-
854. 
Felices, M, S Chu, B Kodal, L Bendzick, C Ryan, AJ Lenvik, KLM Boylan, HC Wong, APN 
Skubitz, JS Miller, and MA Geller. IL-15 super-agonist (ALT-803) enhances natural killer (NK) 
cell function against ovarian cancer. Gynecol Oncol. 2017. 145:453 
Geller MA, Cooley S, Judson PL, et al. A Phase II study of allogeneic natural killer cell 
therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98-
107.  
Hermanson DL, Bendzick L, Pribyl L, McCullar V, Vogel RI, Miller JS, et al. Induced 
Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer. Stem 
Cells. 2016;34(1):93-101 
Iliopoulou EG, Kountourakis P, Karamouzis MV, et al. A Phase I trial of adoptive transfer of 
allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer 
Immunol Immunother. 2010;59:1781-9. 
Investigator's Brochure MGA271 (Enoblituzumab). Edition number: 9.0. Release date: 21 
June 2019. 
Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in oncology. 
Biometrics. 2005;61(2):540-5. 
Jing Y, Ni Z, Wu J, et al. Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) 
and the engineering of a non-cleavable version of the receptor in NK cells. PLoS One. 
2015;10:e0121788. 
Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I. Cytotoxic cells with 
specificity for mouse Moloney leukemia cells. Specificity and distribution according to 
genotype. Eur J Immunol. 1975; 5:112-7.  
Kohler MF, Soper JT, Tucker JA Jr, Clarke-Pearson DL. Isolated incisional metastases after 
intraperitoneal radioactive chromic phosphate therapy for ovarian carcinoma. Cancer 
1991;68:1380- 1383.  
Kymriah™ (tisagenlecleucel) suspension for intravenous infusion [Prescribing Information]. 
East Hanover, NJ. Novartis Pharmaceuticals Corporation; 2018.  

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 66 of 79 
CPRC #2020LS001 
 
Lai, P, H Rabinowich, PA Crowley-Nowick, MC Bell, G Mantovani, and TL Whiteside. 
Alterations in expression and function of signal-transducing proteins in tumor-associated T 
and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res. 1996. 2:161 
Lajoie L, Congy-Jolivet N, Bolzec A. ADAM17-mediated shedding of FcγRIIIA on human NK 
cells: identification of the cleavage site and relationship with activation. J Immunol. 
2014;192:741-51. 
Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus grading for cytokine release 
syndrome and neurological toxicity associated with immune effector cells. Biol Blood Marrow 
Transplant. 2019 Apr; 25(4):625-638. 
Malmberg KJ, Carlsten M, Bjӧrklund A, et al. Natural killer cell-mediated immunosurveillance 
of human cancer. Semin Immunol. 2017;31:20-9. 
MacGregor HL, Sayad A, Elia A, et al. High expression of B7-H3 on stromal cells defines 
tumor and stromal compartments in epithelial ovarian cancer and is associated with limited 
immune activation. Journal for ImmunoTherapy of Cancer (2019) 7:357. 
Melero I, Rouzaut A, Motz GT, et al. T-cell and NK-cell infiltration into solid tumors: a key 
limiting factor for efficacious cancer immunotherapy. Cancer Discov. 2014:4:522-6. 
Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo 
expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051-7. 
Mirrakhimov AE, Ali AM, Khan M, et.al. Tumor lysis syndrome in solid tumors: an up to date 
review of the literature. Rare Tumors. 2014; 6(2):5389. 
Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms 
and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive 
metastatic breast cancer. J Clin Oncol. 2008:26:1789-96. 
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - 
assessment and management of toxicities. Nat Rev Clin Oncol. 2018; 15(1):47-62. 
Patankar, MS, Y Jing, JC Morrison, JA Belisle, FA Lattanzio, Y Deng, NK Wong, HR Morris, 
A Dell, and GF Clark. Potent suppression of natural killer cell response mediated by the 
ovarian tumor marker CA125. Gynecol Oncol. 2005. 99:704 
O'Quigley J, Shen LZ. Continual Reassessment Method: a likelihood approach.  
Biometrics. 1996;52:395-405. 
Romee R, Foley B, Lenvik T, et al. NK cell CD16 surface expression and function is regulated 
by a disintegrin and metalloprotease-17 (ADAM17). Blood. 2013;121:3599-608. 
Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer 
cells exhibit enhanced responses against myeloid leukemia. 
Sci Transl Med. 
2016;8:357ra123. 
Smyth MJ, Hayakawa Y, Takeda K, et al. New aspects of natural-killer-cell surveillance and 
therapy of cancer. Nat Rev Cancer. 2002;2(11):850-61. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 67 of 79 
CPRC #2020LS001 
 
Tonn T, Schwabe D, Klingemann, et al. Treatment of patients with advanced cancer with the 
natural killer cell line NK-92. Cytotherapy. 2013;15:1563-70. 
Veluchamy JP, Kok N, van der Vliet HJ, et al. The rise of allogeneic natural killer cells as a 
platform for cancer immunotherapy: recent innovations and future developments. Front 
Immunol. 2017;8:631. 
Vlad AM, Budiu RA, Wang Y, et al. A phase II trial of intraperitoneal interleukin-2 in patients 
with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother. 
2010 Feb;59(2):293-301.  
Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008; 27:5932-
43. 
Wang R, Law JJ, Stutzman NC, et al. Natural killer cell-produced IFN-g and TNF-a induce 
target cell cytolysis through up-regulation of ICAM-1. J Leukoc Biol. 2012;91:299-309. 
Wang W, Erbe A, Hank J, et al. NK cell-mediated antibody-dependent cellular cytotoxicity in 
cancer immunotherapy. Front Immunol. 2015;6:368. 
Wang Y, J Wu, R Newton, NS Bahaie, C Long, and B Walcheck. ADAM17 cleaves CD16b 
(FcgammaRIIIb) in human neutrophils. Biochim Biophys Acta. 2013. 1833:680 
Wu J, HK Mishra, and B Walcheck. Role of ADAM17 as a regulatory checkpoint of CD16A in 
NK cells and as a potential target for cancer immunotherapy. J Leukoc Biol. 2019. 105:1297 
Yescarta® (axicabtagene ciloleucel) suspension for intravenous infusion [Prescribing 
Information]. Santa Monica, CA. Kite Pharma, Inc; 2019. 
Zhang X, Sullivan P, Soslow R, et al. Tumor Associated Endothelial Expression of B7-H3 
Predicts Survival in Ovarian Carcinomas. Mod Pathol. Aug 2010. 23(8), 1104-12. 
Zohar S, Chevret S. The continual reassessment method: comparison of Bayesian 
stopping rules for dose-ranging studies. Stat Med. 2001;20:2827–43. 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 68 of 79 
CPRC #2020LS001 
 
Appendix I – GOG PS Scale and NYHA Classification 
 
 
GOG 
Score 
Activity Level  
0 
Fully active, unrestricted activities of daily living  
1 
Ambulatory, but restricted in strenuous activity  
2 
Ambulatory, and capable of self care. Unable to work. Out 
of bed for greater than 50% of waking hours  
3 
Limited self care, or confined to bed or chair 50% of 
waking hours. Needs special assistance  
4 
Completely disabled, and no self care  
5 
Dead  
 
 
 
NYHA Class 
Patients with Cardiac Disease (Description of HF Related Symptoms) 
Class I (Mild) 
Patients with cardiac disease but without resulting in limitation of physical 
activity. Ordinary physical activity does not cause undue fatigue, 
palpitation (rapid or pounding heart beat), dyspnea (shortness of breath), 
or anginal pain (chest pain). 
Class II (Mild) 
Patients with cardiac disease resulting in slight limitation of physical 
activity. They are comfortable at rest. Ordinary physical activity results in 
fatigue, palpitation, dyspnea, or anginal pain 
Class III (Moderate) 
Patients with cardiac disease resulting in marked limitation of physical 
activity. They are comfortable at rest. Less than ordinary activity causes 
fatigue, palpitation, dyspnea, or anginal pain. 
Class IV (Severe) 
Patients with cardiac disease resulting in the inability to carry on any 
physical activity without discomfort. Symptoms of heart failure or the 
anginal syndrome may be present even at rest. If any physical activity is 
undertaken, discomfort is increased. 
The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of 
the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994:253-256. 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 69 of 79 
CPRC #2020LS001 
 
Appendix II - iRECIST version 1.1 
Modified Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 for 
Immune-Based Therapeutics (iRECIST)  
1 
DEFINITIONS OF DISEASE 
1.1 
Measurable Disease 
Measurable lesions are defined as those that can be accurately measured in ≥1 dimension 
(longest diameter to be recorded) as >10 mm with computed tomography (CT) scan (with 
minimum slice thickness of 5 mm), or >10 mm caliper measurement by clinical exam, or >20 mm 
by chest X-ray. 
Pathological lymph nodes may also be considered as target on-target lesions. To be considered 
pathologically enlarged and measurable (target lesion), a lymph node must be ≥15 mm in short 
axis when assessed by CT scan (minimum slice thickness of 5 mm). Lymph nodes with a short 
axis ≥10 mm but <15 mm should be considered non-target lesions. Lymph nodes that have a 
short axis <10 mm are considered nonpathologic and should not be recorded as target lesions at 
baseline. 
1.2 
Nonmeasurable Disease 
Nonmeasurable disease comprises all other lesions (or sites of disease), including small lesions 
(longest diameter <10 mm or pathological lymph notes with ≥10 mm but <15 mm short axis) as 
well as leptomeningeal disease, ascites, pleural or pericardial effusions, inflammatory breast 
disease, lymphangitis cutis or pulmonis, abdominal masses, or organomegaly identified by 
physical exam that is not measurable by reproducible imaging techniques. 
1.3 
Other Disease 
Bone lesions: Bone scan, positron emission tomography (PET) scan or plain films are not 
considered adequate imaging techniques to measure bone lesions. However, these techniques 
can be used to confirm the presence or disappearance of bone lesions. Lytic bone lesions or 
mixed lytic-blastic lesions, with identifiable soft tissue components, that can be evaluated by 
cross-sectional imaging techniques such as CT or MRI can be considered as measurable lesions 
if the soft-tissue component meets the definition of measurability described in Section 1.1 above. 
Blastic bone lesions are considered nonmeasurable. 
Cystic lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable or nonmeasurable) since they are, by 
definition, simple cysts. Cystic lesions thought to represent cystic metastases can be considered 
as measurable lesions, if they meet the definition of measurability described in Section 1.1 above. 
However, if non-cystic lesions are present in the same subject, these are preferred for selection 
as target lesions. 
Tumor lesions situated in a previously irradiated area, or in an area subjected to other locoregional 
therapy, are not considered measurable unless there has been demonstrated progression in the 
lesion. Such lesions should not be selected as target lesions when other measurable lesions are 
available. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 70 of 79 
CPRC #2020LS001 
 
2 
DEFINITIONS OF TARGET AND NON-TARGET LESIONS 
2.1 
Target Lesions 
Up to a maximum of 5 measurable lesions total (and a maximum of 2 lesions per organ) 
representative of all involved organs should be identified as target lesions and recorded and 
measured at baseline. Target lesions should be selected on the basis of their size (lesions with 
the longest diameter) and their suitability for accurate and reproducible repeated measurements 
(either by imaging techniques or clinically). 
2.2 
Non-target Lesions 
All other lesions (or sites of disease) should be identified as non-target lesions and should also 
be recorded at baseline. Measurements are not required and these lesions should be followed as 
“present”, “absent” or “unequivocal progression.”  Non-target lesions include measurable lesions 
that exceed the maximum number per organ or total of all involved organs as well as 
nonmeasurable lesions. It is possible to record multiple non-target lesions involving the same 
organ as a single item on the case report form (e.g., “multiple enlarged pelvic lymph nodes” or 
“multiple liver metastases”). Measurements of these lesions are not required, but the presence or 
absence of each should be noted throughout follow-up. 
3 
GUIDELINES FOR EVALUATION OF DISEASE 
3.1 
Methods of Assessment 
CT is the best currently available and reproducible method to measure lesions selected for 
response assessment. MRI is also acceptable in certain situations (e.g., for body scans). The 
minimum slice thickness should be 5 mm. If slice thickness is <5 mm, the minimum size for a 
measurable lesion should be twice the slice thickness. 
The utility of other methods other than CT or MRI to assess response are summarized as follows: 
 
Clinical lesions will only be considered measurable when they are superficial (e.g., skin 
nodules and palpable lymph nodes). In the case of skin lesions, documentation by color 
photography, including a ruler to estimate the size of the lesion, is recommended. 
 
Chest X-ray may be used to follow measurable lesions when they are clearly defined and 
surrounded by aerated lung. However, CT of lesions of the chest is preferred. 
 
When available, functional fluorodeoxyglucose (FDG)-PET data can be used to complement 
CT data when assessing PD but is not a formal component of disease assessment for solid 
tumors. 
 
Ultrasound should not be used as a method of assessment. 
 
The use of endoscopy or laparoscopy for objective tumor evaluation is not advised. However, 
these techniques can be useful to confirm complete pathological response when biopsies are 
obtained or to determine disease relapse. 
 
Tumor markers can be followed but cannot be used alone to assess response or progression. 
If markers are initially above the upper normal limit, they must normalize for a subject to be 
considered in CR. 
 
Cytology or histology can be used to differentiate between PR and CR in rare cases 
(e.g., residual lesions in tumor types, such as germ-cell tumors, where known residual benign 
tumors can remain). Because an effusion may be a side effect of some treatments, the 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 71 of 79 
CPRC #2020LS001 
 
cytological confirmation of the neoplastic origin of any effusion that appears or worsens during 
treatment is mandatory to differentiate between CR, PR, SD, and PD. 
3.2 
Reproducibility of Assessment 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Ideally, the same individual should 
consistently perform assessments. 
Imaging-based evaluation is preferred to evaluation by clinical examination when both methods 
have been used to assess the antitumor effect of a treatment. To ensure comparability, the 
baseline radiology/scans and subsequent radiology/scans to assess response should be 
performed using identical techniques whenever possible (e.g., scans performed immediately 
following bolus contrast administration should be made with a standard volume of contrast, the 
identical contrast agent, and the same scanner). 
3.3 
Determination of Tumor Response and Progression 
Determination of tumor responses and disease progression should follow the following guidelines: 
 
All baseline evaluations should be performed as closely as possible to the beginning of 
treatment within the protocol-defined screening period. 
 
All sites of disease will be followed as either target or non-target lesions, as categorized at 
baseline. All measurable lesions up to a maximum of 2 lesions per organ or 5 lesions in total, 
representative of all involved organs, should be identified as target lesions, while all other 
lesions (either additional measurable lesions or nonmeasurable lesions) will be classified as 
non-target lesions. 
 
All measurements will be taken and recorded in metric notation using a ruler or calipers. A 
sum of the diameters for all target lesions will be calculated and reported as the baseline sum 
of the diameters. For solid tumor lesions, only the long axis is added to the sum and for lymph 
nodes, only the short axis is added to the sum. 
 
All lesions (nodal and non-nodal) recorded at baseline should have their actual measurements 
recorded at each subsequent evaluation, even when very small (e.g., 2 mm). If the lesion has 
likely disappeared, the measurement should be recorded as 0 mm. If a target lesion (nodal or 
non-nodal) becomes so faint on radiographic imaging that an exact measurement cannot be 
assigned, then a default value of 5 mm (minimum slice thickness) should be assigned. 
 
The short axis measurement of any lymph node that is considered a target lesion should 
continue to be recorded even if the node regresses to <10 mm. However, because this may 
prevent the sum of lesions from being zero even if CR criteria are met, target lymph nodes 
that regress to <10 mm can be considered to have become normal for purposes of CR 
calculation. 
 
At each post-baseline tumor assessment, the sum of the diameters of the index lesions will 
be added together to calculate the sum of target lesions. Comparison of subsequent 
assessments to the smallest sum of the diameters (nadir tumor burden), including the baseline 
sum if that is the smallest sum of the diameters during the study, will be used to characterize 
objective tumor progression in the measurable dimensions of the disease. 
 
New lesions should be assessed and categorized as measurable or nonmeasurable. Any new, 
measurable lesions (as defined in Section 1.1 above) (up to a maximum of 5 measurable new 
lesions total [2 new lesions per organ]) representative of all involved organs, will be measured 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 72 of 79 
CPRC #2020LS001 
 
and recorded separately on the case report form but not included in the sum of lesions for 
target lesions identified at baseline. Other measurable and nonmeasurable lesions will be 
recorded as new lesions non-target. If a new lesion is identified (thus meeting the criteria for 
iUPD) and the subject is clinically stable, treatment should be continued. New lesions do not 
have to resolve for subsequent iSD or iPR providing that the next assessment did not confirm 
progression. New lesions do not need to meet the criteria for new target lesion to result in 
iUPD (or iCPD). New lesions that are either target or non-target can drive iUPD or iCPD. 
Progressive disease is confirmed (iCPD) in the new lesion category if the next imaging 
assessment confirms additional new lesions or a further increase in new lesion size from iUPD 
(sum of measures increase in new target lesion ≥5 mm, any increase for new non-target 
lesions).  
4 
 TUMOR RESPONSE AND PROGRESSION CRITERIA 
Responses will be categorized as iCR, iPR, iSD, iUPD, or iCPD. In addition, a response category 
of non-evaluable (NE) is provided for situations in which there is inadequate information to 
otherwise categorize response status. 
4.1 
Target Lesions 
The definitions of response and progression for target lesions is: 
 
iCR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or 
non-target) must have reduction in short axis to <10 mm.  
 
iPR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference 
the Screening (baseline) sum diameters.  
 
iUPD: At least a 20% increase in the sum of diameters of target lesions, taking as reference 
the smallest sum on study (this includes the Screening (baseline) sum if that is the smallest 
on study). In addition to the relative increase of 20%, the sum must also demonstrate an 
absolute increase of at least 5 mm. iUPD can be assigned multiple times as long as iCPD is 
not confirmed at the next assessment.  
 
iCPD: if the target lesion response was iUPD at the last timepoint and shows a further increase 
in tumor burden as evidenced (as applicable) by a ≥5 mm increase in sum of measures of 
target lesions. However, the criteria for iCPD (after iUPD) are not considered to have been 
met if iCR, iPR, or iSD criteria (compared with baseline and as defined by RECIST 1.1) are 
met at the next assessment after iUPD. The status is reset and iCR, iPR, or iSD should then 
be assigned; and if no change is detected, then the timepoint response is iUPD. 
 
iSD: Neither sufﬁcient shrinkage to qualify for iPR nor sufﬁcient increase to qualify for iUPD. 
 
NE: In a subject who does not have iUPD or iCPD, the inability to perform a response 
assessment due to missing data regarding target lesions. 
4.2 
Non-target Lesions 
While some non-target lesions may be measurable, they need not be measured and instead 
should be assessed only qualitatively at the timepoints specified in the protocol. The definitions 
of response and progression for non-target lesions are: 
 
iCR:  Disappearance of all non-target lesions, normalization of an elevated tumor marker level, 
and all lymph nodes nonpathologic in size (<10 mm in the short axis). 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 73 of 79 
CPRC #2020LS001 
 
 
Non-iCPD/non-iUPD:  Persistence of ≥1 non-target lesion and/or maintenance of tumor 
marker level above the ULN. 
 
iUPD:  Unequivocal progression of existing non-target lesion representing substantial 
worsening in non-target disease such that, even in the presence of stable or decreasing target 
disease, the overall tumor burden appears to have increased. iUPD can be assigned several 
times as long as iCPD is not confirmed at the next assessment. 
 
iCPD:  Progressive disease in the non-target lesion category is confirmed if subsequent 
imaging shows a further increase from iUPD. The criteria for iCPD are not judged to have 
been met if RECIST 1.1 criteria for complete response or non-iCR/non-iUPD are met after a 
previous iUPD. The status is reset and iCR or non-iCR/non-iUPD is assigned. If no change is 
detected, the timepoint response is iUPD. 
 
NE:  In a subject who does not have iUPD or iCPD, the inability to perform a response 
assessment due to missing data regarding non-target lesions. 
4.3 
Determination of Response or Progression at Each Timepoint 
The occurrence of tumor response or progression will be determined at each timepoint. The table 
below provides a summary of the overall response or progression status at each timepoint. 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 74 of 79 
CPRC #2020LS001 
 
Assignment of Timepoint Response Using iRECIST 
Target 
Lesions a 
Non-target 
Lesions a 
New 
Lesions a 
Time Point Response 
No prior iUPD b 
Prior iUPD b, c 
iCR 
iCR 
No 
iCR 
iCR 
iCR 
Non-iCR/ 
Non-iUPD 
No 
iPR 
iPR 
iPR 
Non-iCR/ 
Non-iUPD 
No 
iPR 
iPR 
iSD 
Non-iCR/ 
Non-iUPD 
No 
iSD 
iSD 
iUPD with no 
change OR 
decrease from 
last timepoint 
iUPD with no 
change OR 
decrease from 
last timepoint 
Yes 
N/A 
New lesions confirm iCPD if new lesions were 
previously identified and increase in size 
(≥5 mm in SOM for new target lesions or any 
increase for new non-target lesions) or number. 
If no change in new lesions (size or number) 
from the last timepoint, remains iUPD. 
iSD, iPR, iCR 
iUPD 
No 
iUPD 
Remains iUPD unless iCPD confirmed based on 
further increase in size of non-target disease 
(need not meet RECIST 1.1 criteria for 
unequivocal PD). 
iUPD 
Non-iCR/ 
Non-iUPD, or 
iCR 
No 
iUPD 
Remains iUPD unless iCPD confirmed based on 
a further increase in SOM of at least 5 mm, 
otherwise remains iUPD. 
iUPD 
iUPD 
No 
iUPD 
Remains iUPD unless iCPD confirmed based on 
further increase in: 
 Previously identified target lesion iUPD SOM 
≥5 mm and/or 
 Non-target lesion iUPD (prior assessment – 
need not be unequivocal PD) 
iUPD 
iUPD 
Yes 
iUPD 
Remains iUPD unless iCPD confirmed based on 
further increase in: 
 Previously identified target lesion iUPD SOM 
≥5 mm and/or 
 Previously identified non-target lesion iUPD 
(need not be unequivocal) and/or 
 Size or number of new lesions previously 
identified  
Non-iUPD/PD 
Non-iUPD/PD 
Yes 
iUPD 
Remains iUPD unless iCPD confirmed based on 
increase in size or number of new lesions 
previously identified. 
iCPD, confirmed progressive disease; iCR, complete response; iPR, partial response; iSD, stable disease; 
iUPD, unconfirmed progressive disease; N/A, not applicable; SOM, sum of measures.  
a Using RECIST 1.1 principles. If no PD occurs, RECIST 1.1 and iRECIST categories for CR, PR, and SD would 
be the same.  
b In any lesion category.  
c Previously identified in assessment immediately prior to this timepoint. 
Reference:  Seymour et al. 2017. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 75 of 79 
CPRC #2020LS001 
 
4.4 
Best Overall Response and Confirmation of Tumor Status 
For iRECIST, the best overall response (iBOR) recorded from the start of treatment until the end 
of treatment will be determined. iUPD will not override a subsequent best overall response of iSD, 
iPR, or iCR, meaning that iPR or iSD can be assigned even if new lesions have not regressed, or 
if unequivocal progression (non-target lesions) remains unchanged, providing that the criteria for 
iCPD are not met. iCR or iPR must be confirmed at a second tumor assessment obtained at >4 
weeks from the assessment at which iCR or iPR was first observed. Confirmation requirements 
for each successive set of 2 scans in determining iBOR are provided the table below. 
 
Best Overall iRECIST Response Assessment Considering Requirement for Confirmation 
Response Category 
at First Timepoint 
Response Category at 
Subsequent Timepoint 
Best Overall Response 
iCR 
iCR 
iCR 
iCR 
iPR 
iUPD unless minimum criteria for iSD met, a 
in which case iSD (possible iPR b) 
iCR 
iSD 
iSD if minimum criteria for iSD met, a 
otherwise iUPD if no further assessment 
iCR 
iUPD 
iSD if minimum criteria for iSD met, a 
otherwise iUPD if no further assessment 
iCR 
NE 
iSD if minimum criteria for iSD met, a 
otherwise NE 
iPR 
iCR 
iPR 
iPR 
iPR 
iPR 
iPR 
iSD 
iSD 
iPR 
iUPD 
iSD if minimum criteria for iSD met, a 
otherwise iUPD if no further assessment 
iPR 
NE 
iSD if minimum criteria for iSD met, a 
otherwise NE 
NE 
NE 
NE 
iBOR, best overall response; iCR, complete response; NE, not evaluable; iPR, partial response; iSD, stable 
disease; iUPD, unconfirmed progressive disease.  
a Assignment of iSD requires that at least one post-baseline scan was obtained at least 4 weeks from start 
of study therapy and met criteria for iSD or better response. 
b If a true iCR occurs at the first timepoint, then any disease seen at a subsequent timepoint (even disease 
meeting PR criteria relative to baseline) results in a iBOR of iUPD (because the disease must have 
reappeared after the iCR). The BOR assessment would depend on whether the minimum duration for 
iSD was met. For a subject who retrospectively had only an apparent iCR (with small lesions still present, 
ie the subject had iPR, not iCR) at the first timepoint, the original iCR should be converted to an iPR and 
the iBOR should be assessed as iPR. 
Reference:  Eisenhauer et al. 2009. 
 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 76 of 79 
CPRC #2020LS001 
 
Appendix III – Expected Toxicities - Preparative Regimen and IL-2  
Cyclophosphamide 
Common 
Less Common 
Rare, but may be serious 
 low white blood cell count with 
increased risk of infection  
 hair loss or thinning, including face 
and body hair (usually grows back 
after treatment)  
 nausea  
 vomiting  
 loss of appetite  
 sores in mouth or on lips  
 bleeding from bladder, with blood 
in urine  
 diarrhea  
 long-term or short-term infertility 
(inability to have children) in 
women and men 
 low platelet count (mild) 
with increased risk of 
bleeding  
 darkening of nail beds  
 acne  
 tiredness  
 infection 
 fetal changes if you 
become pregnant while 
taking 
cyclophosphamide  
 
 heart problems with high doses, with chest pain, 
shortness of breath, or swollen feet 
 severe allergic reactions 
 skin rash  
 scarring of bladder 
 kidney damage (renal tubular necrosis) which can 
lead to kidney failure 
 heart damage, with trouble getting your breath, 
swelling of feet, rapid weight gain 
 scarring of lung tissue, with cough and shortness 
of breath 
 second cancer, which can happen years after 
taking this drug 
 death from infection, bleeding, heart failure, 
allergic reaction, or other causes 
 
Fludarabine 
Common 
Less Common 
Rare, but may be serious 
 low white blood cell count with 
increased risk of infection  
 low platelet count with increased 
risk of bleeding  
 low red blood cell count (anemia) 
with tiredness and weakness 
 tiredness (fatigue)  
 nausea  
 vomiting  
 fever and chills 
 infection 
 pneumonia  
 diarrhea  
 loss of appetite 
 weakness 
 pain 
 
 numbness and tingling in hands and/or feet 
related to irritation of nerves  
 changes in vision  
 agitation  
 confusion 
 clumsiness 
 seizures 
 coma  
 cough  
 trouble breathing  
 intestinal bleeding 
 weakness  
 death due to effects on the brain, infection, 
bleeding, severe anemia, skin blistering, or other 
causes 
 
Interleukin-2 (IL-2) 
Common 
Less Common 
Rare, but may be serious 
 fever and chills or flu-like symptoms  
 generalized flushing (redness) of 
the face and body, or skin rash.  
 nausea or vomiting  
 lowered blood pressure  
 diarrhea  
 low blood counts increasing the risk 
of infection, anemia and//or 
bleeding  
 changes in mental status, such as 
confusion, drowsiness or memory 
loss  
 fast heartbeats  
 lowered urine output  
 changes in liver function  
 generalized aches and pains  
 swelling of the face, ankles or legs  
 respiratory congestion or 
breathing difficulty  
 itching  
 mouth sores  
 poor appetite  
 fatigue  
 weight gain or loss  
 Infection  
 irregular heartbeats  
 dizziness  
 dry or peeling skin  
 injection site reactions  
 
 capillary leak syndrome 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 77 of 79 
CPRC #2020LS001 
 
Appendix IV – Management of Clinical Neurotoxicity 
Management of clinical neurotoxicity, i.e., encephalopathy syndrome, status epilepticus, and raised intracranial 
pressure, should follow current recommendations for CAR-T-cell therapies (Neelapu 2018; Table A-1, Table A-
2, and Table A-3) and/or institutional practice. 
  
Table A-1 
Recommendations for the Management of Encephalopathy Syndrome 
Grade 
Management  
Grade 1 
 
 Vigilant supportive care; aspiration precautions; IV hydration  
 Withhold oral intake of food, medicines, and fluids, and assess swallowing  
 Convert all oral medications and/or nutrition to IV if swallowing is impaired  
 Avoid medications that cause central nervous system depression  
 Low doses of lorazepam (0.25–0.5 mg IV every 8 hours) or haloperidol (0.5 mg IV every 6 hours) can be 
used, with careful monitoring, for agitated subjects  
 Neurology consultation  
 Fundoscopic exam to assess for papilloedema  
 MRI of the brain with and without contrast; diagnostic lumbar puncture with measurement of opening 
pressure; MRI spine if the subject has focal peripheral neurological deficits; CT scan of the brain can be 
performed if MRI of the brain is not feasible  
 Daily 30-minute EEG until toxicity symptoms resolve; if no seizures are detected on EEG, continue 
levetiracetam 750 mg every 12 hours  
 If EEG shows non-convulsive status epilepticus, treat as per algorithm in Table A-2  
 Consider anti-IL-6 therapy with tocilizumab 8 mg/kg a IV or siltuximab 11 mg/kg IV, if encephalopathy is 
associated with concurrent CRS  
Grade 2 
 
 Supportive care and neurological work-up as described for grade 1 encephalopathy  
 Tocilizumab 8 mg/kg a IV or siltuximab 11 mg/kg IV if associated with concurrent CRS  
 Dexamethasone 10 mg IV every 6 hours or methylprednisolone 1 mg/kg IV every 12 hours if refractory to 
anti-IL-6 therapy, or for encephalopathy without concurrent CRS  
 Consider transferring subject to ICU if encephalopathy associated with Grade ≥2 CRS  
Grade 3 
 
 Supportive care and neurological work-up as indicated for Grade 1 encephalopathy 
 ICU transfer is recommended  
 Anti-IL-6 therapy if associated with concurrent CRS, as described for Grade 2 encephalopathy and if not 
administered previously  
 Corticosteroids as outlined for Grade 2 encephalopathy if symptoms worsen despite anti-IL-6 therapy, or 
for encephalopathy without concurrent CRS; continue corticosteroids until improvement to Grade 1 
encephalopathy and then taper  
 Stage 1 or 2 papilloedema with CSF opening pressure <20 mmHg should be treated as per algorithm 
presented in Table A-3 
 Consider repeat neuroimaging (CT or MRI) every 2–3 days if subject has persistent grade ≥3 
encephalopathy 
Grade 4 
 
 Supportive care and neurological work-up as outlined for Grade 1 encephalopathy  
 ICU monitoring; consider mechanical ventilation for airway protection  
 Anti-IL-6 therapy and repeat neuroimaging as described for Grade 3 encephalopathy  
 High-dose corticosteroids continued until improvement to Grade 1 encephalopathy and then taper; for 
example, methylprednisolone IV 1 g/day for 3 days, followed by rapid taper at 250 mg every 12 hours for 2 
days, 125 mg every 12 hours for 2 days, and 60 mg every 12 hours for 2 days  
 For convulsive status epilepticus, treat as per algorithm in Table A-2  
 Stage ≥3 papilloedema, with a CSF opening pressure ≥20 mmHg or cerebral oedema, should be treated 
as per algorithm in Table A-3 
CAR, chimeric antigen receptor; CSF, cerebrospinal fluid; CRS, cytokine release syndrome; CT, computed tomography (scan); EEG, 
electroencephalogram; ICU, intensive care unit; IV, intravenous; MRI, magnetic resonance imaging. 
 a 
Maximum amount of tocilizumab per dose is 800 mg. 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 78 of 79 
CPRC #2020LS001 
 
Table A-1 
Recommendations for the Management of Encephalopathy Syndrome 
Grade 
Management  
Reference: Neelapu 2018. 
 
Table A-2 
Recommendations for the Management of Status Epilepticus 
Status Epilepticus 
Type 
Management 
Non-convulsive 
status epilepticus  
 
 Assess airway, breathing, and circulation; check blood glucose  
 Lorazepam a 0.5 mg IV, with additional 0.5 mg IV every 5 minutes, as needed, up to a total 
of 2 mg to control electrographical seizures  
 Levetiracetam 500 mg IV bolus, as well as maintenance doses  
 If seizures persist, transfer to ICU and treat with phenobarbital loading dose of 60 mg IV  
 Maintenance doses after resolution of non-convulsive status epilepticus are as follows: 
lorazepam 0.5 mg IV every 8 hours for three doses; levetiracetam 1,000 mg IV every 12 
hours; phenobarbital 30 mg IV every 12 hours  
Convulsive status 
epilepticus  
 
 Assess airway, breathing, and circulation; check blood glucose  
 Transfer to ICU  
 Lorazepam a 2 mg IV, with additional 2 mg IV to a total of 4 mg to control seizures  
 Levetiracetam 500 mg IV bolus, as well as maintenance doses  
 If seizures persist, add phenobarbital treatment at a loading dose of 15 mg/kg IV  
 Maintenance doses after resolution of convulsive status epilepticus are: lorazepam 0.5 mg 
IV every 8 hours for three doses; levetiracetam 1,000 mg IV every 12 hours; phenobarbital 
1–3 mg/kg IV every 12 hours  
 Continuous electroencephalogram monitoring should be performed, if seizures are 
refractory to treatment  
ICU, intensive care unit; IV, intravenous. 
NOTE: All indicated doses of medication are for adult subjects.  
a 
Lorazepam is the recommended benzodiazepine because it is short-acting, compared with diazepam, and has been widely used in the 
management of seizures.  
Reference: Neelapu 2018. 
 
 
 
 

MT2020-07:  FT516 and Enoblituzumab in Women with Recurrent Gynecological Cancers 
  
 
 
 
 
 
January 11, 2022 
Page 79 of 79 
CPRC #2020LS001 
 
 
Table A-3 
Recommendation for the Management of Raised Intracranial Pressure (ICP) 
Stage 
Management 
Stage 1 or 2 papilledema a with CSF 
opening pressure of <20 mmHg without 
cerebral edema  
 Acetazolamide 1,000 mg IV, followed by 250–1,000 mg IV every 12 hours 
(adjust dose based on renal function and acid-base balance, monitored 
1–2 times daily)  
Stage 3, 4, or 5 papilloedema, a with any 
sign of cerebral oedema on imaging 
studies, or a CSF opening pressure of  
≥20 mmHg  
 
 Use high-dose corticosteroids with methylprednisolone IV 1 g/day, as 
recommended for Grade 4 encephalopathy syndrome (Table A-1)  
 Elevate head end of the subject’s bed to an angle of 30 degrees  
 Hyperventilation to achieve target partial pressure of arterial carbon 
dioxide (PaCO2) of 28–30 mmHg, but maintained for no longer than 24 
hours  
 Hyperosmolar therapy with either mannitol (20 g/dL solution) or 
hypertonic saline (3% or 23.4%, as detailed below) 
 Mannitol: initial dose 0.5–1 g/kg; maintenance at  
0.25–1 g/kg every 6 hours while monitoring metabolic profile and 
serum osmolality every 6 hours, and withhold mannitol if serum 
osmolality is ≥320 mOsm/kg, or the osmolality gap is ≥40  
 Hypertonic saline: initial 250 mL of 3% hypertonic saline; maintenance 
at 50–75 mL/h while monitoring electrolytes every 4 hours, and 
withhold infusion if serum Na levels reach ≥155 mEq/L  
 For subjects with imminent herniation: initial 30 mL of 23.4% 
hypertonic saline; repeat after 15 minutes, if needed  
 If subject has ommaya reservoir, drain CSF to target opening pressure of 
<20 mmHg  
 Consider neurosurgery consultation and IV anesthetics for burst-
suppression pattern on electroencephalography  
 Metabolic profiling every 6 hours and daily CT scan of head, with 
adjustments in usage of the aforementioned medications to prevent 
rebound cerebral edema, renal failure, electrolyte abnormalities, 
hypovolemia, and hypotension  
CSF, cerebrospinal fluid; CT, computed tomography (scan); IV, intravenous. 
NOTE: All medication doses indicated are for adults.  
a 
Papilledema grading should be performed according to the modified Frisén scale. 
Reference: Neelapu 2018.